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Abstract: Verletzungen des adulten zentralen Nervensystems ziehen schwerwiegende klinische Konse-
quenzen nach sich, da die Möglichkeiten zur funktionellen Kompensation minimal sind. Auch spontane
Zellerneuerung, regeneratives axonales Wachstum und Wiederherstellung von synaptischen Kontakten
werden kaum je festgestellt. Das Wissen über das sich entwickelnde und über das adulte Nervensys-
tem wächst rasch, und während der letzten Jahrzehnte hat sich unser Verständnis von Neuropathologie
gewandelt. Wir wissen nun, dass die fehlende funktionelle Erholung nach Verletzungen des Zentralner-
vensystems teilweise von Molekülen abhängt, welche die Nervenzellen umgeben. Dabei sind vor allem
die Myelin- assoziierten, inhibierenden Moleküle zu erwähnen. Ausserdem fehlt verletzten Neuronen die
Fähigkeit, ein Genexpressionsmuster zu aktivieren, das ihnen erlaubt, Axone zum Wachstum zu veran-
lassen. In dieser Dissertation werden bestimmende Faktoren des axonalen Wachstums untersucht und
besprochen. Eine Möglichkeit, die mit dem Myelin zusammenhängende Wachstumshemmung teilweise
zu überwinden, ist, die Bindung eines inhibitorischen Myelinbestandteils, Nogo-A, an seine neuronalen
Rezeptoren zu blockieren, indem ein monoklonaler Antikörper, IN-1, verabreicht wird. Um die Effekte von
IN-1 detailliert zu untersuchen, benutzen wir ein Tiermodell bei welchem wir Ratten den Kortikospinal-
trakt einseitig durchtrennen. Wie früher gezeigt wurde, verstärken sich dabei strukturelle Plastizität und
funktionelle Erholung. Wir zeigen zum ersten Mal auf der elektronenmikroskopischen Ebene, dass neu
auswachsende Nervenfasern im verletzten adulten Zentralnervensystem fähig sind, histologisch intakte
Synapsen zu bilden. Die intrazellulären Mechanismen, die es Neuronen erlauben, Axone auswachsen zu
lassen, werden nach wie vor schlecht verstanden. Wir versuchen hier anhand von Gen-Chip-Analysen
einen weiten Überblick über die Anpassung der Transkription nach axonalen Verletzungen zu gewinnen.
Wir untersuchen die Genexpression von lumbalen dorsalen Ganglienzellen der adulten Ratte nach Ver-
letzung der peripheren und auch der zentralen Nervenfasern. Die so gewonnenen Resultate vergleichen
wir mit der Genexpression derselben Neuronenpopulation während der Embryonalentwicklung. Die pe-
riphere und die zentrale Axotomie lösen klar unterscheidbare Antworten im Zellkörper aus. Für beide
Verletzungsmuster gilt, dass die Expression von mehr als 50 Genen reguliert wird. Im Vergleich mit
der Embryonalenwicklung stellen wir fest, dass für die Regeneration von peripheren Nerven keine voll-
ständige Rekapitulation des embryonalen Expressionsmusters nötig ist. Wir untersuchen auch die durch
eine Verletzung ausgelösten Änderungen der Gen- und Protein-Expression genauer, dies anhand von zwei
Genen, Glypican-1 und dem peripheren Benzodiazepin-Rezeptor (PBR). Unsere Resultate zeigen, dass
sich die Antwort des Zellsomas auf Verletzungen nicht nur auf der Ebene der Transkription und Trans-
lation zeigt, sondern vielmehr auch in der Lokalisierung und im Transport der Proteine. Im Falle von
Glypican-1 legen unsere Resultate nahe, dass dem Protein im Rahmen des axonalen Wachstums und
der Richtungszuweisung von auswachsenden Neuriten, zum Beispiel durch die Beeinflussung von Slit-
Robo-Interaktionen, eine Rolle zukommt. Wir liefern eine erste detaillierte Beschreibung der Expression
der Mitglieder der Slit- und Robo-Familien in verletzten und unverletzten adulten dorsalen Ganglien-
zellen. Ebenso zeigen wir mit verschiedenen histologischen Techniken zum ersten Mal die Induktion
von PBR nach einer Axotomie in dorsalen Ganglien, und zwar spezifisch in kleinkalibrigen Neuronen.
Wir demonstrieren das Vorhandensein des intakten PBR mit Hilfe von Liganden-Bindungsversuchen.
Zusammengefasst zeigen die in dieser Dissertation präsentierten Resultate, dass in Neuronen des adulten
verletzten Nervensystems die Fähigkeit zur strukturellen Reorganisation und zum Aufbau von synaptis-
chen Verbindungen erhalten bleibt, wenn ihre Umgebung es erlaubt. Wir beschreiben die Genexpression
im Zellkörper, welche eine bestimmende Grösse der neuronalen Wachstumskapazität ist, nach neuronalen
Verletzungen. Ausserdem zeigen wir, dass diese Antwort nicht auf die Transkription beschränkt bleibt,
sondern auch post-transkriptionelle Mechanismen beinhaltet. The clinical consequences of adult central
nervous system injuries are extremely severe since there is only a minor capability for functional com-
pensation and an almost complete absence of cell renewal and axonal re-growth and re-connection. The
understanding of the developing and adult nervous system is progressing rapidly. In the past decades
the growing comprehension has been continuously extended onto neuropathological conditions. We know
now that the lack of recovery following injuries of the central nervous system is partly due to environ-
mental, most importantly myelin- associated inhibitory factors, and partly to the inability of injured
neurons to mount a gene expression profile that allows axonal growth. In this thesis determinants of
axonal growth are examined and discussed. A way to partially overcome myelin-derived growth inhibi-
tion, is to prevent Nogo-A from binding to neuronal receptors by applying monoclonal antibody IN-1. To
further investigate the effect of IN-1, rats with unilaterally injured cortical spinal tract were treated with
IN-1. This approach was previously shown to enhance structural plasticity and functional recovery in
the treated rats. Using light- and electron-microscopy, we show for the first time that outgrowing nerve
fibers can form new, ultrastructurally intact synaptic contacts in the adult nervous system following an
identical model as described above. The intracellular mechanisms that enable neurons to grow axons are
poorly understood. Microarray analysis offers a way to screen for transcriptional adaptations following
axonal injury. We investigate gene expression in lumbar dorsal root ganglia of the adult rat following
central or peripheral nerve injury and compare the results with the developmental gene expression in
the same population of neurons. Peripheral and central axotomy induce clearly distinguishable cell body
responses. For both injury paradigms the expression for more than 50 genes is regulated. The com-
parison to developmental stages, when axonal outgrowth occurs, reveals that a complete recapitulation
of a developmental gene expression pattern is not necessary for the regeneration of peripheral nerves.
We further investigate injury-induced transcriptional and post-transcriptional changes, exemplified by
two genes, glypican-1 and the peripheral benzodiazepine receptor (PBR). Our results show that the cell
body response to injury is not restricted to changes in transcription and translation, but also involves
post-translational effects, such as protein localization and transport. For glypican-1 the presented results
support functions in axonal growth and guidance, e.g. by involvement in slit-robo interactions. We
provide a first detailed description of the expression of slit and robo family members in the adult injured
and non-injured dorsal root ganglion. Using different histological techniques we show for the first time
the induction of the PBR specifically in small-diameter dorsal root ganglion neurons after nerve injury.
Ligand binding studies indicate the presence of correctly assembled PBR following injury. In summary,
the results reported in this study show evidence that neurons in the adult nervous system retain capacities
for structural reorganization and re-connection following injury if faced with a permissive environment.
We characterize the transcriptional cell body response of neurons to injury, an important determinant of
the neuronal growth capacity. Additionally, we show that the cell body response is not simply regulated
at the level of transcription but is specified by post-transcriptional mechanisms.
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Summary 
 
 
The clinical consequences of adult central nervous system injuries are extremely severe since 
there is only a minor capability for functional compensation and an almost complete absence 
of cell renewal and axonal re-growth and re-connection. The understanding of the developing 
and adult nervous system is progressing rapidly. In the past decades the growing 
comprehension has been continuously extended onto neuropathological conditions. We know 
now that the lack of recovery following injuries of the central nervous system is partly due to 
environmental, most importantly myelin-associated inhibitory factors, and partly to the 
inability of injured neurons to mount a gene expression profile that allows axonal growth.  
 
In this thesis determinants of axonal growth are examined and discussed. A way to partially 
overcome myelin-derived growth inhibition, is to prevent Nogo-A from binding to neuronal 
receptors by applying monoclonal antibody IN-1. To further investigate the effect of IN-1, 
rats with unilaterally injured cortical spinal tract were treated with IN-1.  This approach was 
previously shown to enhance structural plasticity and functional recovery in the treated rats. 
Using light- and electron-microscopy, we show for the first time that outgrowing nerve fibers 
can form new, ultrastructurally intact synaptic contacts in the adult nervous system following 
an identical model as described above. 
 
The intracellular mechanisms that enable neurons to grow axons are poorly understood.  
Microarray analysis offers a way to screen for transcriptional adaptations following axonal 
injury. We investigate gene expression in lumbar dorsal root ganglia of the adult rat following 
central or peripheral nerve injury and compare the results with the developmental gene 
expression in the same population of neurons. Peripheral and central axotomy induce clearly 
distinguishable cell body responses. For both injury paradigms the expression for more than 
50 genes is regulated. The comparison to developmental stages, when axonal outgrowth 
occurs, reveals that a complete recapitulation of a developmental gene expression pattern is 
not necessary for the regeneration of peripheral nerves.  
 
We further investigate injury-induced transcriptional and post-transcriptional changes, 
exemplified by two genes, glypican-1 and the peripheral benzodiazepine receptor (PBR). Our 
results show that the cell body response to injury is not restricted to changes in transcription 
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and translation, but also involves post-translational effects, such as protein localization and 
transport. For glypican-1 the presented results support functions in axonal growth and 
guidance, e.g. by involvement in slit-robo interactions. We provide a first detailed description 
of the expression of slit and robo family members in the adult injured and non-injured dorsal 
root ganglion. Using different histological techniques we show for the first time the induction 
of the PBR specifically in small-diameter dorsal root ganglion neurons after nerve injury. 
Ligand binding studies indicate the presence of correctly assembled PBR following injury. 
 
In summary, the results reported in this study show evidence that neurons in the adult nervous 
system retain capacities for structural reorganization and re-connection following injury if 
faced with a permissive environment. We characterize the transcriptional cell body response 
of neurons to injury, an important determinant of the neuronal growth capacity. Additionally, 
we show that the cell body response is not simply regulated at the level of transcription but is 
specified by post-transcriptional mechanisms. 
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Zusammenfassung 
 
 
Verletzungen des adulten zentralen Nervensystems ziehen schwerwiegende klinische 
Konsequenzen nach sich, da die Möglichkeiten zur funktionellen Kompensation minimal 
sind. Auch spontane Zellerneuerung, regeneratives axonales Wachstum und 
Wiederherstellung von synaptischen Kontakten werden kaum je festgestellt. Das Wissen über 
das sich entwickelnde und über das adulte Nervensystem wächst rasch, und während der 
letzten Jahrzehnte hat sich unser Verständnis von Neuropathologie gewandelt. Wir wissen 
nun, dass die fehlende funktionelle Erholung nach Verletzungen des Zentralnervensystems 
teilweise von Molekülen abhängt, welche die Nervenzellen umgeben. Dabei sind vor allem 
die Myelin- assoziierten, inhibierenden Moleküle zu erwähnen. Ausserdem fehlt verletzten 
Neuronen die Fähigkeit, ein Genexpressionsmuster zu aktivieren, das ihnen erlaubt, Axone 
zum Wachstum zu veranlassen.  
 
In dieser Dissertation werden bestimmende Faktoren des axonalen Wachstums untersucht und 
besprochen. Eine Möglichkeit, die mit dem Myelin zusammenhängende Wachstumshemmung 
teilweise zu überwinden, ist, die Bindung eines inhibitorischen Myelinbestandteils, Nogo-A, 
an seine neuronalen Rezeptoren zu blockieren, indem ein monoklonaler Antikörper, IN-1, 
verabreicht wird. Um die Effekte von IN-1 detailliert zu untersuchen, benutzen wir ein 
Tiermodell bei welchem wir Ratten den Kortikospinaltrakt einseitig durchtrennen. Wie früher 
gezeigt wurde, verstärken sich dabei strukturelle Plastizität und funktionelle Erholung. Wir 
zeigen zum ersten Mal auf der elektronenmikroskopischen Ebene, dass neu auswachsende 
Nervenfasern im verletzten adulten Zentralnervensystem fähig sind, histologisch intakte 
Synapsen zu bilden. Die intrazellulären Mechanismen, die es Neuronen erlauben, Axone 
auswachsen zu lassen, werden nach wie vor schlecht verstanden. Wir versuchen hier anhand 
von Gen-Chip-Analysen einen weiten Überblick über die Anpassung der Transkription nach 
axonalen Verletzungen zu gewinnen. Wir untersuchen die Genexpression von lumbalen 
dorsalen Ganglienzellen der adulten Ratte nach Verletzung der peripheren und auch der 
zentralen Nervenfasern. Die so gewonnenen Resultate vergleichen wir mit der Genexpression 
derselben Neuronenpopulation während der Embryonalentwicklung. Die periphere und die 
zentrale Axotomie lösen klar unterscheidbare Antworten im Zellkörper aus. Für beide 
Verletzungsmuster gilt, dass die Expression von mehr als 50 Genen reguliert wird. Im 
Vergleich mit der Embryonalenwicklung stellen wir fest, dass für die Regeneration von 
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peripheren Nerven keine vollständige Rekapitulation des embryonalen Expressionsmusters 
nötig ist.  
 
Wir untersuchen auch die durch eine Verletzung ausgelösten Änderungen der Gen- und 
Protein-Expression genauer, dies anhand von zwei Genen, Glypican-1 und dem peripheren 
Benzodiazepin-Rezeptor (PBR). Unsere Resultate zeigen, dass sich die Antwort des 
Zellsomas auf Verletzungen nicht nur auf der Ebene der Transkription und Translation zeigt, 
sondern vielmehr auch in der Lokalisierung und im Transport der Proteine. Im Falle von 
Glypican-1 legen unsere Resultate nahe, dass dem Protein im Rahmen des axonalen 
Wachstums und der Richtungszuweisung von auswachsenden Neuriten, zum Beispiel durch 
die Beeinflussung von Slit-Robo-Interaktionen, eine Rolle zukommt. Wir liefern eine erste 
detaillierte Beschreibung der Expression der Mitglieder der Slit- und Robo-Familien  in 
verletzten und unverletzten adulten dorsalen Ganglienzellen. Ebenso zeigen wir mit 
verschiedenen histologischen Techniken zum ersten Mal die Induktion von PBR nach einer 
Axotomie in dorsalen Ganglien, und zwar spezifisch in kleinkalibrigen Neuronen. Wir 
demonstrieren das Vorhandensein des intakten PBR mit Hilfe von Liganden-
Bindungsversuchen. 
 
Zusammengefasst zeigen die in dieser Dissertation präsentierten Resultate, dass in Neuronen 
des adulten verletzten Nervensystems die Fähigkeit zur strukturellen Reorganisation und zum 
Aufbau von synaptischen Verbindungen erhalten bleibt, wenn ihre Umgebung es erlaubt. Wir 
beschreiben die Genexpression im Zellkörper, welche eine bestimmende Grösse der 
neuronalen Wachstumskapazität ist, nach neuronalen Verletzungen. Ausserdem zeigen wir, 
dass diese Antwort nicht auf die Transkription beschränkt bleibt, sondern auch post-
transkriptionelle Mechanismen beinhaltet. 
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Introduction 
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The adult mammalian central nervous system (CNS) is known for its inability to 
spontaneously repair large structural damages in a functionally meaningful way. Therefore 
extensive injuries to the adult CNS, e.g. spinal cord injury or stroke as well as many 
degenerative neurological diseases, e.g. Parkinson’s disease, Alzheimer’s disease or multiple 
sclerosis, often permanently disable normal functioning of the CNS and may cause 
maladaptive responses evoking additional severe symptoms.  
 
In marked contrast to the adult CNS, the embryonic and early postnatal developing CNS of 
higher vertebrates can compensate for structural damage to a high degree, a feature already 
recognized by Ramón y Cajal in 1928. Neurons of the peripheral nervous system (PNS) retain 
their regenerative potential throughout development and adulthood.  
 
While the CNS was looked at as a rigid and stable interconnection of neurons during the first 
half of the last century, it has become more and more clear that the system’s plasticity is 
surprisingly high in terms of normal physiological processing but also in response to 
pathological conditions including partial, smaller scale injuries. These changes can occur at 
different levels along the neuraxis, e.g. in the hippocampal formation or in the dorsal horn of 
the spinal cord. Different domains of a neuron, such as the dendrites, axons or synapses can 
be altered and the result may be reflected in histological, electrophysiological or behavioral 
changes. Utilizing the system’s intrinsic plastic potential has become an indispensable tool for 
clinical rehabilitation. 
 
Regardless of local plasticity, the CNS has to ensure that its overall structure and the basic 
connectivity underlying adequate physiological processing are maintained during the lifetime 
of an individual. Therefore, cooperative mechanisms are needed to ensure the CNS’s stability 
on the one hand, and to regulate local neuronal plasticity on the other hand, in order to 
balance the system. Structural alterations of the nervous system by mechanical impact, 
ischemia or degeneration seem to favor processes that try to preserve the integrity of the 
spared system rather than allowing extensive adaptations to occur.  
 
Replacing cells that are lost through disease or injury, enhancing the plasticity of the CNS and 
its compensatory capacity following injury, as well as axonal regeneration, are major goals of 
today’s basic research. 
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This introduction gives a brief overview about spinal cord injury in humans and about some 
aspects of its current treatment and rehabilitation. After that, current attempts to promote 
regeneration and functional recovery in animal models are described. The following section 
focuses on axonal regeneration and neuronal plasticity in terms of its control by one major 
myelin-associated growth inhibitor, Nogo-A. Finally, the present understanding of the 
neuronal response to axotomy is summarized.  
 
 
Spinal cord injury – where are we at? 
 
At the beginning of the twenty-first century spinal cord injury and injuries to the CNS in 
general still have devastating consequences for the individual suffering from it. There is no 
cure, but the knowledge about underlying molecular and cellular processes is growing 
tremendously fast, giving hope that ways of treating patients can be developed. Current 
experimental approaches that may lay the basis for effective clinical treatments are discussed 
in the following section of this chapter.  
 
During the last 20 years the incidence of traumatic spinal cord injuries in industrialized 
countries (10 - 30 cases per 106 inhabitants and year) has hardly changed (Sett and Crockard, 
1991). Between 1997 and 1999, 126 patients suffering from spinal cord injury were treated at 
the Duke of Cornwall Spinal Treatment Centre, Salisbury District Hospital. 45% of the 
injuries were due to road traffic accidents, 34% were due to domestic and industrial accidents, 
15% to injuries at sports and 6% were caused by self harm and criminal assault. 45% of the 
patients were hospitalized with cervical injuries, 40% with injuries of the thoracic spinal cord 
and in 15% the lumbar portion was affected (Grundy and Swain, 2002). In Switzerland the 
numbers may differ slightly because of a higher incidence of injuries at sports mostly due to 
skiing accidents. From 123 patients with acute traumatic spinal cord injury treated at the 
Spinal Cord Injury Centre, University Hospital Balgrist, Zürich, 70% were men and 30% 
women. Whereas the proportion of accidents between sexes was almost equal for road traffic 
accidents and injuries at sports, males accounted for 90% of accidents at work whereas 
women caused 80% of the incidents of self harm. In general more than 50% of the patients are 
between 16 and 30 years old (Dietz, 2001).  The overall mortality after spinal cord trauma 
was around 13% within the first 7 years following the injury between 1973 and 1980 (DeVivo 
et al., 1987). Since then life expectancy has increased substantially accompanied by a 
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significantly better quality of life (Wahle, 1990; DeVivo and Richards, 1992; DeVivo et al., 
1999).  
 
For the early clinical assessment and for measuring the clinical outcome of sensory and motor 
deficits following spinal cord injury the ASIA (American Spinal Injury Association)-scale is 
internationally accepted, widely used and allows determination of the level of the lesion 
(Ditunno, 1994; Maynard et al., 1997). In addition, the documentation of functional 
impairments using the walking index for spinal cord injury (WISCI) and the spinal cord 
independence measure (SCIM), is crucial to assess remaining nerve functions, to control 
rehabilitative and therapeutic approaches and to estimate the quality of life of the patient 
(Ditunno et al., 2000; Itzkovich et al., 2002). A standardized assessment and evaluation 
protocol for monitoring the extent and characteristics of recovery after spinal cord injury, 
including clinical tests as well as neurophysiological and neuroradiological techniques, is 
currently being established and evaluated by five European spinal cord injury centers with the 
goal to provide a basis for testing and control of new therapeutic interventions (Curt et al., 
2004).  
 
The management of spinally injured patients following treatment of immediately life-
threatening associated injuries and surgical stabilization of the vertebral column aims at I) the 
protection from secondary cytotoxic tissue damage, II) preventing complications arising from 
autonomously controlled organs, from the blood, the skin, joints and limbs, and III) 
rehabilitation and training of  preserved functions and reflexes. In Europe, commonly applied 
clinical treatments include the infusion of methylprednisolone (within 3 hours after injury: 
30mg/kg within 15min i.v. followed by 5.4mg/kg/hour for 23 hours; if commenced 3-8 hours 
after injury: initial bolus and infusion for 47 hours). Methylprednisolone is a potent anti-
inflammatory glucocorticoid with inhibitory effects on lipid peroxidation lowering the 
production of free radicals following injury (Hall, 1992; Hall et al., 1992). 
Methylprednisolone was tested in controlled and randomized clinical trials (National Acute 
Spinal Cord Injury Studies, NASCIS I,II & III) where small but significant neurological 
improvements were described in patients with complete as well as incomplete spinal cord 
injury (Bracken et al., 1984; Bracken and Holford, 1993; Bracken et al., 1997). The way 
methylprednisolone acts, is still very controversial. In animal models no positive effect on 
secondary cell death of high-dose methylprednisolone treatment after SCI could be found, but 
a clear reduction in the number of neutrophils and macrophages invading the lesion site was 
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observed (Bartholdi and Schwab, 1995). The effects of methylprednisolone may also depend 
on the status of the subject’s inflammatory system prior to the injury (L. Schnell, M. Gullo & 
M.E. Schwab, unpublished data). So far no other drug has been proven clinically helpful in 
preventing secondary damage following SCI.  
 
Patients with high cervical injuries may need respiratory support. Generally, a central venous 
catheter is used for several days to supply the body with fluids, electrolytes and human 
albumin depending on the measured central venous pressure. Whenever the heart rate falls 
below 50 beats/min, atropine (0.25-0.5mg, s.c., every 8 hours) is used to block 
parasympathetic suppression of the heart. Anticoagulation should be started within 72 hours 
after the injury using low molecular weight heparin if there are no medical or surgical 
contraindications (0.2-0.6ml Fraxiparin® s.c. 1x/day). Due to the risk of acute peptic 
ulceration proton pump inhibitors or H2-receptor antagonists are administered starting at the 
4th day following the injury. Pain is controlled using morphine analogues, e.g. fentanyl, and in 
case of missing motility of the bowels neostigmin is a potential drug that can be used. The 
initial bladder management includes a suprapubic catheter avoiding over-distension of the 
organ. The patient should be turned every 2 to 3 hours between supine and right and left 
lateral positions to prevent pressure sores. Daily, joints need to be passively moved to prevent 
stiffness and contractures. All these early treatment strategies together have strongly 
improved the outlook for people with SCI. Surgical and medical treatment strategies are 
discussed in more detail elsewhere (Dietz, 2001; Grundy and Swain, 2002).  
 
In recent years it has become clear that the spinal cord contains capabilities for use-dependent 
plasticity following injuries. Mostly based on findings in lower vertebrates, rodents, cats and 
primates, a concept for local spinal circuits controlling locomotion has arisen (for reviews see 
(Harkema, 2001; Fouad and Pearson, 2004)). Adaptive plasticity in the human spinal cord 
after spinal cord injury is evident and weight-supported locomotion training on a treadmill has 
become a promising tool to enhance functional recovery of walking in patients with 
incomplete injuries. The method consists of partial body-weight support and manual 
assistance of leg movements providing patterned afferent feedback to the spinal cord. 
Typically training is carried out for months with gradually reduced weight support and 
diminished assistance to initiate the swing phase and for stepping. Initial comprehensive 
studies testing the efficacy of assisted locomotor training revealed sustained stepping 
movements in acute and chronic clinically incomplete injured patients. The beneficial effects 
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could be maintained for months or years after completion of training and in cases where self-
sustained walking was achieved, no specific training is needed to retain the improvements in 
everyday life (Wernig et al., 1995; Wernig et al., 1998; Wirz et al., 2001). In contrast to 
patients with incomplete spinal cord injury, training of patients with complete spinal cord 
injury did not lead to sustained stepping movements of the legs, possibly because of the total 
absence of supraspinal input. Treadmill training of patients with complete spinal cord injuries 
is able though to temporarily alter EMG patterns, i.e. restoring the alternating flexor – 
extensor and right leg – left leg activation, along with a reduction of spasticity (Dietz et al., 
1995). Very recently a robotic device assisting and controlling stepping on a treadmill, named 
the Lokomat® , was developed (Colombo et al., 2001). It allows better control and 
reproducibility of assisted leg movements and reduces the number of therapists needed and 
the physical strain on therapists during the training procedure. Combination of treadmill 
training with either pharmacological treatment or electrical stimulation has produced first 
encouraging results but has not yet led to routinely used therapeutic protocols.  
 
 
Experimental Approaches to Enhance Functional Recovery after Spinal Cord Injury 
 
Based on transplantation experiments showing cortical axons of a rabbit growing into a 
peripheral nerve transplant, Ramón y Cajal suggested that trophic and tropic factors might be 
present in substrates permissive for axonal growth. Based on this assumption the lack of 
supportive factors in the adult CNS was hypothesized (Tello, 1911; Cajal, 1928). Many years 
later the importance of peripheral nerves as a permissive substrate for axons to regenerate 
could be demonstrated (Richardson et al., 1980; David and Aguayo, 1981; Schwab and 
Thoenen, 1985). The use of substrates allowing axonal growth, as peripheral nerve grafts, 
olfactory ensheating glial cells, Schwann cells, stem cells and fetal tissue, became one 
experimental approach to bridge the injured area in the spinal cord of rodents (Paino and 
Bunge, 1991; Cheng et al., 1996; Xu et al., 1997; Ramon-Cueto et al., 2000; Coumans et al., 
2001; Li et al., 2003). Many but not all of these bridging paradigms resulted in enhanced 
recovery of locomotion (Takami et al., 2002). The use of a polymer scaffold seeded with stem 
cells was shown to improve open field locomotion (Teng et al., 2002). This experiment 
combined pure grafting approaches with the idea of providing a microenvironment that 
actively supports neurite outgrowth and cell survival by trophic signals.  
 
 
16
Administration of neurotrophic factors, namely brain-derived neurotrophic factor (BDNF) and 
neurotrophin-3 (NT-3), was tested successfully in a variety of spinal cord injury models. 
Neurotrophic factors were delivered via  mini-osmotic pumps, a tool that can also be used in 
human patients, or by transplanting genetically modified cells or more recently viral vectors 
(Kobayashi et al., 1997; Zhou et al., 2003). Depending on the experimental model, treatment 
with neurotrophic factors resulted in enhanced sprouting and regeneration of descending 
motor tracts, partial functional recovery or decreased cell death of axotomized neurons 
(Schnell et al., 1994; Grill et al., 1997; Shibayama et al., 1998).  
 
Earlier this year two research groups succeeded in reducing secondary apoptotic cell death 
following spinal cord injury and in promoting locomotor recovery by pharmacologically 
blocking P2X7 purine receptors or by neutralizing the pro-apoptotic CD95 ligand by applying 
CD95 ligand specific antibodies (Demjen et al., 2004; Wang et al., 2004).  
 
Many extracellular matrix constituents influence axonal outgrowth, either in a supportive or 
repressive way. Following spinal cord injury the environment at the site of injury changes 
profoundly, leading among other changes to elevated expression of chondroitin sulphate 
proteoglycans (CSPGs), that can effectively inhibit axonal re-growth into the site of injury, 
and to the build-up of the glial scar (for reviews see (Rhodes and Fawcett, 2004; Silver and 
Miller, 2004)). Breaking down the glycosaminoglycan side chains of CSPGs by injections of 
chondroitinase ABC was demonstrated to enhance regeneration of descending motor as well 
as ascending sensory fiber tracts and to result in some improvement of locomotor and 
proprioceptive behavior (Bradbury et al., 2002). The inhibition of intracellular PKC-γ enabled 
dorsal root ganglion (DRG) neurons to partially overcome CSPG- and myelin-induced 
inhibition in the dorsal columns following spinal cord injury (Sivasankaran et al., 2004). 
 
Another promising approach originated in findings from culture experiments where it was 
shown that in the presence of optimal concentrations of NGF, axons of PNS neurons heavily 
grew into explants derived from the sciatic nerve but not into optic nerve explants (Schwab 
and Thoenen, 1985), leading to the assumption that specific neurite growth inhibitors must be 
associated with CNS tissues. Following experiments localized the inhibitory action to mature, 
differentiated oligodendrocytes in the CNS, consistent with results that showed strong 
inhibition of axon outgrowth on CNS white matter (Schwab and Caroni, 1988). By partial 
purification and biochemical characterization of rat myelin two protein fractions with 
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inhibitory action were isolated with molecular weights of 35 and 250 kDa, subsequently 
called NI-35 and NI-250 (Caroni and Schwab, 1988b). Later the same components were 
found in CNS material from many other mammals including humans. In 2000 the full length 
cDNA of rat NI-250 and the human homologue were cloned and named Nogo-A (Spillmann 
et al., 1997; Spillmann et al., 1998; Chen et al., 2000; GrandPre et al., 2000; Prinjha et al., 
2000). Disinhibition of axonal growth by interfering with the action of Nogo-A in the CNS 
offers possibilities to learn about CNS plasticity, regeneration and development. The major 
findings involving Nogo-A are further discussed in the next section and in chapter 2. 
 
 
Regulation of Axonal Regeneration and Structural Plasticity by Myelin-associated 
inhibitors 
 
Kennard reported the ability of monkeys with cortical lesions at early postnatal stages to 
develop motor skills, whereas adult monkeys with similar cortical lesions suffered from a 
permanent loss of motor function. Therefore, the Kennard Principle, states that functional 
recovery critically depends on the age of the animal subjected to an injury (Kennard, 1936, 
1938; Teuber, 1974).  
 
Pioneering work on the corticobulbar and corticospinal tract of the hamster provided an 
anatomical correlate for the observation that functional recovery and compensation were more 
pronounced the younger the animal. Unilateral injury of the corticospinal tract (CST) at the 
level of the medulla oblongata (pyramidotomy) in the adult hamster led to nerve fiber 
degeneration and retraction rostrally and caudally from the site of lesion with no axonal re-
growth. In the infant hamster though, if the same operation was performed, severed axons re-
grew via a new pathway to their appropriate target sites in the medulla oblongata and spinal 
cord (Kalil and Reh, 1979). A more detailed study of re-growing CST axons revealed that re-
growing axons did not make their way through the site of the lesion but crossed to the 
contralateral brainstem rostrally from it, that they formed a compact bundle of fibers and grew 
caudally for 6-7mm. Although following an aberrant trajectory, the pattern of termination in 
the dorsal column nuclei and the dorsal horn of the cervical spinal cord seemed normal. 
Synapse formation by re-growing axons was confirmed by electron microscopy. The speed of 
axonal growth was determined to be around 1mm/day, which is somewhat slower than during 
normal development of the CST (2-4mm/day). This response was most pronounced at 4-8 
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days of age whereas no fiber growth was observed if the lesion was performed twenty or more 
days postnatally (Kalil and Reh, 1982). A few years later it could be shown that unilateral 
pyramidotomy in immature hamsters not only evoked a growth response in injured CST axons 
but also in the contralateral intact CST. At local spinal levels, but not in the brainstem, 
collaterals of the uninjured CST sprouted into the denervated side in a topographically 
meaningful way such that axons originating in the somatosensory cortex connected to dorsal 
horn neurons whereas those of the motor cortex terminated primarily in the ventral horn. For 
compensatory axonal growth of the uninjured CST and for axonal re-growth to occur, similar 
permissive time frames were found (Kuang and Kalil, 1990a, b).  
 
The developmental stage of the CNS therefore controls the capacity of axonal growth in 
response to injury, a feature strongly correlated with the progressive myelination of 
developing fiber tracts. The closure of the time window for axonal growth can be delayed by 
X-irradiation of  the developing spinal cord, abolishing myelin formation and oligodendrocyte 
maturation, a procedure that allowed long-distance re-growth of injured CST axons and 
compensatory sprouting of intact CST neurite following partial spinal cord injury and 
pyramidotomy respectively in the rat (Savio and Schwab, 1990; Vanek et al., 1998).  
 
Since the description of NI-35 and NI-250, several additional constituents of myelin apart 
from Nogo-A have been found with inhibitory effects on axonal outgrowth, namely myelin-
associated glycoprotein (MAG) and oligodendrocyte-myelin  glycoprotein (OMgp), 
semaphorin 4D, ephrin B3, netrin-1 and the proteoglycans V2 and brevican (McKerracher et 
al., 1994; Wang et al., 2002). Interestingly, Nogo-A, MAG and OMgp partially share 
receptors and intracellular signaling pathways, including a very recently identified co-
receptor, LINGO-1 (Mi et al., 2004). The issue of receptors and downstream signaling 
components is further discussed in chapter 2.  
 
A monoclonal IgM antibody, mAb IN-1, was raised, recognizing rat NI-250, later cloned as 
Nogo-A (Caroni and Schwab, 1988a). mAb IN-1 proved to be a powerful tool in overcoming 
myelin-derived inhibition in the central nervous system. The application of mAb IN-1, by 
implanting hybridoma cells that produce the antibody into the lateral ventricle of the brain 
following dorsal hemisection of the spinal cord, allowed massive sprouting of injured CST 
fibers rostral to the lesion and more importantly long distance regenerative axonal growth up 
to 11mm beyond the site of injury, an observation that was never observed in control rats 
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(Schnell and Schwab, 1990). In the following years locomotor recovery following partial SCI 
and treatment with mAb IN-1 was reported from various experiments (Bregman et al., 1995; 
Merkler et al., 2001). Currently the effect of a new generation of monoclonal IgG antibodies 
recognizing a specific sequence of Nogo-A is under investigation. The influence of new anti-
Nogo-A antibodies roughly mimicks the effects observed with IN-1, even though the new 
antibodies are applied intrathecally by mini-osmotic pumps (unpublished results, L. Schnell, 
T. Liebscher & M.E. Schwab).  
 
Apart from inducing long-distance axonal regeneration, the action of mAb IN-1 substantially 
enhanced structural plasticity in the adult CNS of the rat contributing to partial recovery of 
fine motor movements following unilateral pyramidotomy, a finding similar to the results 
obtained from experiments in immature hamsters discussed in preceding sections. The injured 
CST established bilateral projections at different levels of the brainstem, including the red 
nucleus, basilar pontine and the dorsal column nuclei and showed enhanced regenerative 
sprouting (Raineteau et al., 1999). Additionally, sprouting of the non-injured CST to the 
denervated side in the spinal cord was observed, resembling structural plasticity found in the 
immature rat CNS (Thallmair et al., 1998; Z'Graggen et al., 1998; Z'Graggen et al., 2000). 
Subsequent experiments showed that the action of mAb IN-1 was not restricted to the CST, 
rather other descending motor systems as the rubrospinal tract participated in reorganizing the 
injured motor system (Raineteau et al., 2001). Compensatory sprouting and re-organization 
can therefore be enhanced by counteracting Nogo-A, an intervention that is followed by 
improved functional recovery. Spontaneous structural re-organization can occur in the 
cortico-propriospinal systems following spinal cord injury. These alterations likely account 
for some of the spontaneous recovery of function seen in injured animals (Bareyre et al., 
2004).  
 
The discovery of receptors and downstream signalling components for myelin-associated 
growth inhibitors offers possibilities to interfere with the inhibitors’ effects at sites different 
from the epitope recognized by mAb IN-1 (see chapter 2). The identification of Nogo-66, one 
of three domains inhibitory for neurite outgrowth, and its receptor NgR, led to the 
development of a peptide, NEP1-40, that competitively antagonized Nogo-66 binding to NgR 
and that was demonstrated to improve functional recovery following spinal cord injury in rats 
(GrandPre et al., 2000; Fournier et al., 2001; GrandPre et al., 2002; Li and Strittmatter, 2003; 
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Oertle et al., 2003). Pharmacological interference with Rho-kinase, a downstream effector of 
NgR produced similar results (Dergham et al., 2002; Fournier et al., 2003).  
 
Surprisingly, constitutive Nogo-A knock-out mice showed different regenerative responses to 
spinal cord injury, depending on the strategy used to get rid of Nogo-A, Nogo-A/-B or Nogo-
A/-B and –C. One research group found some regenerative axonal growth in a selective 
Nogo-A knock-out mouse line that showed compensatory up-regulation of Nogo-B (Simonen 
et al., 2003). Another group reported massive regeneration in a Nogo-A/-B knock-out 
approach, whereas a third group didn’t observe any regenerative reaction in Nogo-A/-B or 
Nogo-A/-B/-C knock-out mice (Kim et al., 2003; Zheng et al., 2003). Further 
characterization, analyses and inducible knock-out systems may provide better insight into the 
specific role of the Nogo proteins. As with the Nogo knock-out animals, the gross anatomy of 
the brain seemed normal in NgR knock-out mice, in which a reactive over-expression of 
Nogo-A was found. Behaviorally this knock-out mouse displayed hypoactivity and motor 
impairments. Following spinal cord injury CST axons did not regenerate, an unexpected result 
comparable though to results obtained from MAG-deficient mice, whereas raphe- and 
rubrospinal tract partially regenerated and helped functional recovery (Bartsch et al., 1995; 
Kim et al., 2004). 
 
 
The Neuron’s Intrinsic Growth Capacity and Response to Axotomy 
 
During the development of the nervous system a series of events need to occur in a precisely 
defined temporal and spatial frame. Neurons and glial cells are generated from multipotent 
precursors. Cells move to their final location within the CNS by radial and tangential 
migration. These processes are paralleled and followed by axonal outgrowth and guidance 
leading to target selection and synapse formation. Neurons that actively grow neurites during 
development are characterized by the specific array of proteins they express which allows 
them to elongate (Fawcett, 1992). Classically these proteins comprise cytoskeletal proteins 
such as actins, neurofilaments, tubulins and microtubule-associated proteins, the proteins 
encoded by certain immediate early genes, and the prototypical growth associated protein 
GAP-43 which is strongly expressed in neurons along the growing axon as well as in the 
growth cone. Neuronal GAP-43 expression decreases when connections with target cells are 
established during maturation of the corticospinal tract and in dorsal root ganglion (DRG) 
neurons (Fitzgerald et al., 1991; Karimi-Abdolrezaee et al., 2002). GAP-43 expression 
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therefore correlates with the intrinsic capacity of neurons to extend axons during 
development. Constitutive GAP-43 knock-out mice reveal pathfinding defects whereas the 
neurite growth rate seems normal (Strittmatter et al., 1995). When maturation of the nervous 
system is complete, GAP-43 expression is very low, but can still be detected in specific areas 
of the CNS known for their plastic potential such as the olfactory bulb, the hippocampal 
formation and the superficial laminae of the dorsal horn (Kapfhammer and Schwab, 1994).  
 
Cutting the sciatic nerve in the adult rat leads to major changes in gene expression with 
hundreds of genes being up- or down-regulated. Microarray analysis is a powerful tool to 
detect changes in mRNA expression in the DRG following sciatic nerve transection  
(Costigan et al., 2002; Xiao et al., 2002). Overall cellular changes after axotomy are called the 
cell body response to injury (Lieberman, 1971). This cell body response allows DRG neurons 
to re-grow their peripheral axons and to re-innervate target structures following axotomy of 
their peripheral branch. In contrast to injury to the peripheral branch, the cell body reaction is 
much more moderate after injury to the central branch as in the case of dorsal rhizotomy or 
spinal cord injury. For example, the regeneration associated protein GAP-43 is not induced 
following dorsal rhizotomy whereas it is re-expressed at high levels following peripheral 
axotomy in DRG neurons (Woolf et al., 1990; Chong et al., 1992; Chong et al., 1994). This 
observation fits well with the fact that central processes of DRG neurons are not regenerating 
through the dorsal root entry zone into the spinal cord, putting GAP-43 forth as a marker for 
cells in a growing state. Transgenic over-expression of GAP-43 induces spontaneous 
sprouting along the axon of axotomized Purkinje cells and co-over-expression of GAP-43 and 
CAP-23, another major growth-associated protein, strongly increases axonal regeneration in 
spinal cord injured mice  (Buffo et al., 1997; Bomze et al., 2001).  
 
The discrepancy of the cell body response between centrally or peripherally injured DRG 
neurons led to the hypothesis that only peripheral injury leads to a full blown cell body 
response, enabling the neuron to regain regenerative axonal growth. On the other hand, the 
neuron displays an abortive reaction to injury of its central branch and fails to induce a growth 
program. Previously, peripherally injured DRG neurons were rendered capable to regenerate 
their central axon into a peripheral nerve graft in the spinal cord (Richardson and Issa, 1984). 
In addition, sciatic nerve transection one week prior to a partial dorsal spinal cord injury 
enabled injured proprioceptive neurites to regenerate across the site of injury in the spinal 
cord (Neumann and Woolf, 1999). Peripheral axotomy alone can induce sprouting of the 
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central branch of injured DRG neurons in the dorsal horn of the spinal cord (Woolf et al., 
1992). The extent of the cell body response of long projection neurons depends critically on 
how far away from the cell body the injury occurs whereas the probability that a neuron dies 
following axotomy is inversely related to the distance between the site of injury and the cell 
body, as specified for retinal ganglion cells (Richardson et al., 1984; Aguayo et al., 1991; 
Berkelaar et al., 1994).  
 
The factors responsible to elicit the cell body response are not well defined. The family of 
neurotrophic factors, including NGF, BDNF, NT-3 and NT-4 in higher vertebrates and their 
receptors, trkA, trkB, trkC, p75, and the more recently identified co-receptor sortilin, likely 
play a key role in inducing and maintaining the cell body response by retrograde transport (for 
review see(Verge et al., 1996); (Schwab, 1977; Nykjaer et al., 2004)). Nerve growth factor 
(NGF), glial-derived neurotrophic factor (GDNF) and NT-3 promoted axonal re-growth and 
synaptic reconnection of specific subpopulations of dorsal root ganglion neurons following 
dorsal rhizotomy (Ramer et al., 2000).  
 
Some immediate early genes are rapidly induced following axotomy and as inducible 
transcription factors, c-jun, JunB, JunD and c-fos may serve as initial regulators of axonal re-
growth. In severed DRG neurons for example, c-jun is only up-regulated following peripheral 
nerve injury but not following dorsal rhizotomy. If the injured central branch of DRG neurons 
is provided with a growth permissive environment that some axonal regeneration can occur, 
c-Jun expression is concomitantly induced in those neurons (Broude et al., 1997). When 
provided with a growth permissive graft, neuronal subpopulations, e.g. neurons of the inferior 
olive, neurons giving rise to mossy fibers and neurons in the deep cerebellar nuclei, were 
enabled to elongate their axons into the graft, in clear contrast to Purkinje cell axons (Dooley 
and Aguayo, 1982; Rossi et al., 1995; Buffo et al., 1997). c-Jun, JunD and GAP-43 were up-
regulated in all classes of neurons showing axonal growth, whereas their expression failed to 
be induced in most of the injured Purkinje cells, controlled by retrogradely transported signals 
along the axon that can be inhibited by the application of mAb IN-1 (Zagrebelsky et al., 
1998). The application of mAb IN-1 was able to induce c-Jun and JunD expression in injured 
Purkinje cells and enabled sprouting of  uninjured Purkinje cell axons (Buffo et al., 2000). 
Over-expression of GAP-43 selectively in Purkinje cells can partially override myelin-derived 
inhibition of neuronal growth (Gianola and Rossi, 2004).  
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These results show evidence that the cell response following injury is regulated both by 
inhibitory, myelin-associated signals as well as inductive signals, e.g. neurotrophic factors. 
The expression of some transcription factors and of GAP-43 can correlate with the ability for 
axonal growth, and their regulation depends on the neuronal subpopulation, the 
developmental stage and the location within the nervous system. 
 
 
Aim of the present work 
 
Myelin-associated inhibitors are mediators of complex signals regulating axonal growth 
(Chapter 2). Their importance becomes apparent relatively late in CNS development, when 
myelination of projecting nerve fiber tracts is established. They play a role in terminating the 
growth-permissive period in early postnatal life during which higher vertebrates can more 
successfully compensate following injuries to the CNS than adults. The presence of myelin-
associated inhibitors in the adult partially explains the lack of regenerative axonal growth and 
restricted compensatory adaptations. In the laboratory of M.E. Schwab, antibodies blocking 
some of the inhibitory activity of Nogo-A were raised and their application led to promising 
results enhancing axonal regeneration and locomotor recovery after partial SCI. In a model of 
unilateral CST lesions, the influence of Nogo-A on structural plasticity and compensatory 
sprouting was examined in great detail. M.E. Schwab and colleagues succeeded in inducing 
structural adaptations and improved voluntary fine movements in adult rats by applying 
antibodies recognizing Nogo-A. On the histological level, fibers of the injured CST 
established bilateral projections at the level of the red nucleus, the basilar pontine nuclei and 
the dorsal column nuclei. The uninjured CST in turn sent sprouts to the denervated side of the 
spinal cord. We want to study whether sprouting CST fibers are actually able to build new 
synaptic contacts following unilateral CST lesions and treatment with anti-Nogo-A antibody 
by carefully analyzing new projections in the basilar pons of adult rats (Chapter 3). Anti-
Nogo-A antibody injections into the cerebellum can induce spontaneous sprouting of Purkinje 
cells, an effect that is paralleled by changes in gene expression in the targeted neurons (Buffo 
et al., 2000). Similar results were obtained by applying IN-1 to intact adult rats where the 
antibodies led to increased numbers of aberrant projections from the CST in parallel with 
increased expression of growth-associated genes, e.g. GAP-43, and transcription factors 
(Bareyre et al., 2002). Therefore, Nogo-A likely participates in regulating the cell body 
response following axotomy in CNS neurons. Except for the regulation of a few genes, e.g. 
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GAP-43 and c-jun, the cell body response to axotomy is not well understood. We aim to 
compare cell body responses of DRG neurons following axotomy of the peripheral versus the 
central branch in more detail. These injury-induced changes are then compared to the 
developmental gene expression pattern in DRG neurons, in order to investigate whether a 
recapitulation of developmental gene expression profiles is necessary for successful 
regeneration or structural reorganization in the spinal cord, as it is seen following peripheral 
axotomy (Chapter 4). Furthermore, we want to identify differentially expressed genes in the 
adult DRG in response to different types of axonal injury, including neuropathic pain models. 
The regulation of a protein’s activity can happen during transcriptional, translational or post-
translational steps. In addition to changes in gene transcription levels we aim to detect post-
transcriptional regulation and pharmacological interactions of selected injury-regulated genes 
(Chapter 5 and 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25
References 
 
Aguayo AJ, Rasminsky M, Bray GM, Carbonetto S, McKerracher L, Villegas-Perez MP, 
Vidal-Sanz M, Carter DA (1991) Degenerative and regenerative responses of injured 
neurons in the central nervous system of adult mammals. Philos Trans R Soc Lond B 
Biol Sci 331:337-343. 
Bareyre FM, Haudenschild B, Schwab ME (2002) Long-lasting sprouting and gene 
expression changes induced by the monoclonal antibody IN-1 in the adult spinal cord. 
J Neurosci 22:7097-7110. 
Bareyre FM, Kerschensteiner M, Raineteau O, Mettenleiter TC, Weinmann O, Schwab ME 
(2004) The injured spinal cord spontaneously forms a new intraspinal circuit in adult 
rats. Nat Neurosci 7:269-277. 
Bartholdi D, Schwab ME (1995) Methylprednisolone inhibits early inflammatory processes 
but not ischemic cell death after experimental spinal cord lesion in the rat. Brain Res 
672:177-186. 
Bartsch U, Bandtlow CE, Schnell L, Bartsch S, Spillmann AA, Rubin BP, Hillenbrand R, 
Montag D, Schwab ME, Schachner M (1995) Lack of evidence that myelin-associated 
glycoprotein is a major inhibitor of axonal regeneration in the CNS. Neuron 15:1375-
1381. 
Berkelaar M, Clarke DB, Wang YC, Bray GM, Aguayo AJ (1994) Axotomy results in 
delayed death and apoptosis of retinal ganglion cells in adult rats. J Neurosci 14:4368-
4374. 
Bomze HM, Bulsara KR, Iskandar BJ, Caroni P, Skene JH (2001) Spinal axon regeneration 
evoked by replacing two growth cone proteins in adult neurons. Nat Neurosci 4:38-43. 
Bracken MB, Holford TR (1993) Effects of timing of methylprednisolone or naloxone 
administration on recovery of segmental and long-tract neurological function in 
NASCIS 2. J Neurosurg 79:500-507. 
Bracken MB, Collins WF, Freeman DF, Shepard MJ, Wagner FW, Silten RM, Hellenbrand 
KG, Ransohoff J, Hunt WE, Perot PL, Jr. (1984) Efficacy of methylprednisolone in 
acute spinal cord injury. Jama 251:45-52. 
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, 
Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Jr., Piepmeier 
J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W (1997) Administration 
of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the 
 
26
treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord 
Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. Jama 
277:1597-1604. 
Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon 
SB (2002) Chondroitinase ABC promotes functional recovery after spinal cord injury. 
Nature 416:636-640. 
Bregman BS, Kunkel-Bagden E, Schnell L, Dai HN, Gao D, Schwab ME (1995) Recovery 
from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature 
378:498-501. 
Broude E, McAtee M, Kelley MS, Bregman BS (1997) c-Jun expression in adult rat dorsal 
root ganglion neurons: differential response after central or peripheral axotomy. Exp 
Neurol 148:367-377. 
Buffo A, Zagrebelsky M, Huber AB, Skerra A, Schwab ME, Strata P, Rossi F (2000) 
Application of neutralizing antibodies against NI-35/250 myelin-associated neurite 
growth inhibitory proteins to the adult rat cerebellum induces sprouting of uninjured 
purkinje cell axons. J Neurosci 20:2275-2286. 
Buffo A, Holtmaat AJ, Savio T, Verbeek JS, Oberdick J, Oestreicher AB, Gispen WH, 
Verhaagen J, Rossi F, Strata P (1997) Targeted overexpression of the neurite growth-
associated protein B-50/GAP-43 in cerebellar Purkinje cells induces sprouting after 
axotomy but not axon regeneration into growth-permissive transplants. J Neurosci 
17:8778-8791. 
Cajal Ry (1928) Degeneration and regeneration of the nervous system, reprint 1959 Edition. 
New York: Hafner. 
Caroni P, Schwab ME (1988a) Antibody against myelin-associated inhibitor of neurite growth 
neutralizes nonpermissive substrate properties of CNS white matter. Neuron 1:85-96. 
Caroni P, Schwab ME (1988b) Two membrane protein fractions from rat central myelin with 
inhibitory properties for neurite growth and fibroblast spreading. J Cell Biol 106:1281-
1288. 
Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA, Christ F, 
Schwab ME (2000) Nogo-A is a myelin-associated neurite outgrowth inhibitor and an 
antigen for monoclonal antibody IN-1. Nature 403:434-439. 
Cheng H, Cao Y, Olson L (1996) Spinal cord repair in adult paraplegic rats: partial restoration 
of hind limb function. Science 273:510-513. 
 
27
Chong MS, Fitzgerald M, Winter J, Hu-Tsai M, Emson PC, Wiese U, Woolf CJ (1992) GAP-
43 mRNA in Rat Spinal Cord and Dorsal Root Ganglia Neurons: Developmental 
Changes and Re-expression Following Peripheral Nerve Injury. Eur J Neurosci 4:883-
895. 
Chong MS, Reynolds ML, Irwin N, Coggeshall RE, Emson PC, Benowitz LI, Woolf CJ 
(1994) GAP-43 expression in primary sensory neurons following central axotomy. J 
Neurosci 14:4375-4384. 
Colombo G, Wirz M, Dietz V (2001) Driven gait orthosis for improvement of locomotor 
training in paraplegic patients. Spinal Cord 39:252-255. 
Costigan M, Befort K, Karchewski L, Griffin RS, D'Urso D, Allchorne A, Sitarski J, Mannion 
JW, Pratt RE, Woolf CJ (2002) Replicate high-density rat genome oligonucleotide 
microarrays reveal hundreds of regulated genes in the dorsal root ganglion after 
peripheral nerve injury. BMC Neurosci 3:16. 
Coumans JV, Lin TT, Dai HN, MacArthur L, McAtee M, Nash C, Bregman BS (2001) 
Axonal regeneration and functional recovery after complete spinal cord transection in 
rats by delayed treatment with transplants and neurotrophins. J Neurosci 21:9334-
9344. 
Curt A, Schwab ME, Dietz V (2004) Providing the clinical basis for new interventional 
therapies: refined diagnosis and assessment of recovery after spinal cord injury. Spinal 
Cord 42:1-6. 
David S, Aguayo AJ (1981) Axonal elongation into peripheral nervous system "bridges" after 
central nervous system injury in adult rats. Science 214:931-933. 
Demjen D, Klussmann S, Kleber S, Zuliani C, Stieltjes B, Metzger C, Hirt UA, Walczak H, 
Falk W, Essig M, Edler L, Krammer PH, Martin-Villalba A (2004) Neutralization of 
CD95 ligand promotes regeneration and functional recovery after spinal cord injury. 
Nat Med 10:389-395. 
Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD, McKerracher L (2002) Rho 
signaling pathway targeted to promote spinal cord repair. J Neurosci 22:6570-6577. 
DeVivo MJ, Richards JS (1992) Community reintegration and quality of life following spinal 
cord injury. Paraplegia 30:108-112. 
DeVivo MJ, Krause JS, Lammertse DP (1999) Recent trends in mortality and causes of death 
among persons with spinal cord injury. Arch Phys Med Rehabil 80:1411-1419. 
DeVivo MJ, Kartus PL, Stover SL, Rutt RD, Fine PR (1987) Seven-year survival following 
spinal cord injury. Arch Neurol 44:872-875. 
 
28
Dietz V (2001) Klinik der Rückenmarkschädigung, 1. Auflage Edition. Stuttgart: 
Kohlhammer. 
Dietz V, Colombo G, Jensen L, Baumgartner L (1995) Locomotor capacity of spinal cord in 
paraplegic patients. Ann Neurol 37:574-582. 
Ditunno JF, Jr. (1994) American spinal injury standards for neurological and functional 
classification of spinal cord injury: past, present and future. 1992 Heiner Sell Lecture 
of the American Spinal Injury Association. J Am Paraplegia Soc 17:7-11. 
Ditunno JF, Jr., Ditunno PL, Graziani V, Scivoletto G, Bernardi M, Castellano V, Marchetti 
M, Barbeau H, Frankel HL, D'Andrea Greve JM, Ko HY, Marshall R, Nance P (2000) 
Walking index for spinal cord injury (WISCI): an international multicenter validity 
and reliability study. Spinal Cord 38:234-243. 
Dooley JM, Aguayo AJ (1982) Axonal elongation from cerebellum into peripheral nervous 
system grafts in the adult rat. Ann Neurol 12:221. 
Fawcett JW (1992) Intrinsic neuronal determinants of regeneration. Trends Neurosci 15:5-8. 
Fitzgerald M, Reynolds ML, Benowitz LI (1991) GAP-43 expression in the developing rat 
lumbar spinal cord. Neuroscience 41:187-199. 
Fouad K, Pearson K (2004) Restoring walking after spinal cord injury. Prog Neurobiol 
73:107-126. 
Fournier AE, GrandPre T, Strittmatter SM (2001) Identification of a receptor mediating 
Nogo-66 inhibition of axonal regeneration. Nature 409:341-346. 
Fournier AE, Takizawa BT, Strittmatter SM (2003) Rho kinase inhibition enhances axonal 
regeneration in the injured CNS. J Neurosci 23:1416-1423. 
Gianola S, Rossi F (2004) GAP-43 overexpression in adult mouse Purkinje cells overrides 
myelin-derived inhibition of neurite growth. Eur J Neurosci 19:819-830. 
GrandPre T, Li S, Strittmatter SM (2002) Nogo-66 receptor antagonist peptide promotes 
axonal regeneration. Nature 417:547-551. 
GrandPre T, Nakamura F, Vartanian T, Strittmatter SM (2000) Identification of the Nogo 
inhibitor of axon regeneration as a Reticulon protein. Nature 403:439-444. 
Grill R, Murai K, Blesch A, Gage FH, Tuszynski MH (1997) Cellular delivery of 
neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery 
after spinal cord injury. J Neurosci 17:5560-5572. 
Grundy D, Swain A (2002) ABC of Spinal Cord Injury, 4th edition Edition. London: BMJ 
Books. 
 
29
Hall ED (1992) The neuroprotective pharmacology of methylprednisolone. J Neurosurg 
76:13-22. 
Hall ED, Braughler JM, McCall JM (1992) Antioxidant effects in brain and spinal cord injury. 
J Neurotrauma 9 Suppl 1:S165-172. 
Harkema SJ (2001) Neural plasticity after human spinal cord injury: application of locomotor 
training to the rehabilitation of walking. Neuroscientist 7:455-468. 
Itzkovich M, Tripolski M, Zeilig G, Ring H, Rosentul N, Ronen J, Spasser R, Gepstein R, 
Catz A (2002) Rasch analysis of the Catz-Itzkovich spinal cord independence 
measure. Spinal Cord 40:396-407. 
Kalil K, Reh T (1979) Regrowth of severed axons in the neonatal central nervous system: 
establishment of normal connections. Science 205:1158-1161. 
Kalil K, Reh T (1982) A light and electron microscopic study of regrowing pyramidal tract 
fibers. J Comp Neurol 211:265-275. 
Kapfhammer JP, Schwab ME (1994) Inverse patterns of myelination and GAP-43 expression 
in the adult CNS: neurite growth inhibitors as regulators of neuronal plasticity? J 
Comp Neurol 340:194-206. 
Karimi-Abdolrezaee S, Verge VM, Schreyer DJ (2002) Developmental down-regulation of 
GAP-43 expression and timing of target contact in rat corticospinal neurons. Exp 
Neurol 176:390-401. 
Kennard MA (1936) Age and other factors in motor recovery from precentral lesions in 
monkeys. Am J Physiol 115:138-146. 
Kennard MA (1938) Reorganization of motor function in the cerebral cortex of monkeys 
deprived of motor and premotor areas in infancy. J Neurophysiol 1:477-496. 
Kim JE, Liu BP, Park JH, Strittmatter SM (2004) Nogo-66 receptor prevents raphespinal and 
rubrospinal axon regeneration and limits functional recovery from spinal cord injury. 
Neuron 44:439-451. 
Kim JE, Li S, GrandPre T, Qiu D, Strittmatter SM (2003) Axon regeneration in young adult 
mice lacking Nogo-A/B. Neuron 38:187-199. 
Kobayashi NR, Fan DP, Giehl KM, Bedard AM, Wiegand SJ, Tetzlaff W (1997) BDNF and 
NT-4/5 prevent atrophy of rat rubrospinal neurons after cervical axotomy, stimulate 
GAP-43 and Talpha1-tubulin mRNA expression, and promote axonal regeneration. J 
Neurosci 17:9583-9595. 
Kuang RZ, Kalil K (1990a) Specificity of corticospinal axon arbors sprouting into denervated 
contralateral spinal cord. J Comp Neurol 302:461-472. 
 
30
Kuang RZ, Kalil K (1990b) Branching patterns of corticospinal axon arbors in the rodent. J 
Comp Neurol 292:585-598. 
Li S, Strittmatter SM (2003) Delayed systemic Nogo-66 receptor antagonist promotes 
recovery from spinal cord injury. J Neurosci 23:4219-4227. 
Li Y, Decherchi P, Raisman G (2003) Transplantation of olfactory ensheathing cells into 
spinal cord lesions restores breathing and climbing. J Neurosci 23:727-731. 
Lieberman AR (1971) The axon reaction: a review of the principal features of perikaryal 
responses to axon injury. Int Rev Neurobiol 14:49-124. 
Maynard FM, Jr., Bracken MB, Creasey G, Ditunno JF, Jr., Donovan WH, Ducker TB, 
Garber SL, Marino RJ, Stover SL, Tator CH, Waters RL, Wilberger JE, Young W 
(1997) International Standards for Neurological and Functional Classification of 
Spinal Cord Injury. American Spinal Injury Association. Spinal Cord 35:266-274. 
McKerracher L, David S, Jackson DL, Kottis V, Dunn RJ, Braun PE (1994) Identification of 
myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. 
Neuron 13:805-811. 
Merkler D, Metz GA, Raineteau O, Dietz V, Schwab ME, Fouad K (2001) Locomotor 
recovery in spinal cord-injured rats treated with an antibody neutralizing the myelin-
associated neurite growth inhibitor Nogo-A. J Neurosci 21:3665-3673. 
Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Sands B, 
Crowell T, Cate RL, McCoy JM, Pepinsky RB (2004) LINGO-1 is a component of the 
Nogo-66 receptor/p75 signaling complex. Nat Neurosci 7:221-228. 
Neumann S, Woolf CJ (1999) Regeneration of dorsal column fibers into and beyond the 
lesion site following adult spinal cord injury. Neuron 23:83-91. 
Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, Jacobsen C, Kliemannel M, 
Schwarz E, Willnow TE, Hempstead BL, Petersen CM (2004) Sortilin is essential for 
proNGF-induced neuronal cell death. Nature 427:843-848. 
Oertle T, van der Haar ME, Bandtlow CE, Robeva A, Burfeind P, Buss A, Huber AB, 
Simonen M, Schnell L, Brosamle C, Kaupmann K, Vallon R, Schwab ME (2003) 
Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. J 
Neurosci 23:5393-5406. 
Paino CL, Bunge MB (1991) Induction of axon growth into Schwann cell implants grafted 
into lesioned adult rat spinal cord. Exp Neurol 114:254-257. 
Prinjha R, Moore SE, Vinson M, Blake S, Morrow R, Christie G, Michalovich D, Simmons 
DL, Walsh FS (2000) Inhibitor of neurite outgrowth in humans. Nature 403:383-384. 
 
31
Raineteau O, Z'Graggen WJ, Thallmair M, Schwab ME (1999) Sprouting and regeneration 
after pyramidotomy and blockade of the myelin-associated neurite growth inhibitors 
NI 35/250 in adult rats. Eur J Neurosci 11:1486-1490. 
Raineteau O, Fouad K, Noth P, Thallmair M, Schwab ME (2001) Functional switch between 
motor tracts in the presence of the mAb IN-1 in the adult rat. Proc Natl Acad Sci U S 
A 98:6929-6934. 
Ramer MS, Priestley JV, McMahon SB (2000) Functional regeneration of sensory axons into 
the adult spinal cord. Nature 403:312-316. 
Ramon-Cueto A, Cordero MI, Santos-Benito FF, Avila J (2000) Functional recovery of 
paraplegic rats and motor axon regeneration in their spinal cords by olfactory 
ensheathing glia. Neuron 25:425-435. 
Rhodes KE, Fawcett JW (2004) Chondroitin sulphate proteoglycans: preventing plasticity or 
protecting the CNS? J Anat 204:33-48. 
Richardson PM, Issa VM (1984) Peripheral injury enhances central regeneration of primary 
sensory neurones. Nature 309:791-793. 
Richardson PM, McGuinness UM, Aguayo AJ (1980) Axons from CNS neurons regenerate 
into PNS grafts. Nature 284:264-265. 
Richardson PM, Issa VM, Aguayo AJ (1984) Regeneration of long spinal axons in the rat. J 
Neurocytol 13:165-182. 
Rossi F, Jankovski A, Sotelo C (1995) Differential regenerative response of Purkinje cell and 
inferior olivary axons confronted with embryonic grafts: environmental cues versus 
intrinsic neuronal determinants. J Comp Neurol 359:663-677. 
Savio T, Schwab ME (1990) Lesioned corticospinal tract axons regenerate in myelin-free rat 
spinal cord. Proc Natl Acad Sci U S A 87:4130-4133. 
Schnell L, Schwab ME (1990) Axonal regeneration in the rat spinal cord produced by an 
antibody against myelin-associated neurite growth inhibitors. Nature 343:269-272. 
Schnell L, Schneider R, Kolbeck R, Barde YA, Schwab ME (1994) Neurotrophin-3 enhances 
sprouting of corticospinal tract during development and after adult spinal cord lesion. 
Nature 367:170-173. 
Schwab ME (1977) Ultrastructural localization of a nerve growth factor-horseradish 
peroxidase (NGF-HRP) coupling product after retrograde axonal transport in 
adrenergic neurons. Brain Res 130:190-196. 
Schwab ME, Thoenen H (1985) Dissociated neurons regenerate into sciatic but not optic 
nerve explants in culture irrespective of neurotrophic factors. J Neurosci 5:2415-2423. 
 
32
Schwab ME, Caroni P (1988) Oligodendrocytes and CNS myelin are nonpermissive 
substrates for neurite growth and fibroblast spreading in vitro. J Neurosci 8:2381-
2393. 
Sett P, Crockard HA (1991) The value of magnetic resonance imaging (MRI) in the follow-up 
management of spinal injury. Paraplegia 29:396-410. 
Shibayama M, Hattori S, Himes BT, Murray M, Tessler A (1998) Neurotrophin-3 prevents 
death of axotomized Clarke's nucleus neurons in adult rat. J Comp Neurol 390:102-
111. 
Silver J, Miller JH (2004) Regeneration beyond the glial scar. Nat Rev Neurosci 5:146-156. 
Simonen M, Pedersen V, Weinmann O, Schnell L, Buss A, Ledermann B, Christ F, Sansig G, 
van der Putten H, Schwab ME (2003) Systemic deletion of the myelin-associated 
outgrowth inhibitor Nogo-A improves regenerative and plastic responses after spinal 
cord injury. Neuron 38:201-211. 
Sivasankaran R, Pei J, Wang KC, Zhang YP, Shields CB, Xu XM, He Z (2004) PKC 
mediates inhibitory effects of myelin and chondroitin sulfate proteoglycans on axonal 
regeneration. Nat Neurosci 7:261-268. 
Spillmann AA, Amberger VR, Schwab ME (1997) High molecular weight protein of human 
central nervous system myelin inhibits neurite outgrowth: an effect which can be 
neutralized by the monoclonal antibody IN-1. Eur J Neurosci 9:549-555. 
Spillmann AA, Bandtlow CE, Lottspeich F, Keller F, Schwab ME (1998) Identification and 
characterization of a bovine neurite growth inhibitor (bNI-220). J Biol Chem 
273:19283-19293. 
Strittmatter SM, Fankhauser C, Huang PL, Mashimo H, Fishman MC (1995) Neuronal 
pathfinding is abnormal in mice lacking the neuronal growth cone protein GAP-43. 
Cell 80:445-452. 
Takami T, Oudega M, Bates ML, Wood PM, Kleitman N, Bunge MB (2002) Schwann cell 
but not olfactory ensheathing glia transplants improve hindlimb locomotor 
performance in the moderately contused adult rat thoracic spinal cord. J Neurosci 
22:6670-6681. 
Tello F (1911) La influencia del neurotropismo en la regeneracion de los nerviosos. Trab Lab 
Invest Biol 9:123-159. 
Teng YD, Lavik EB, Qu X, Park KI, Ourednik J, Zurakowski D, Langer R, Snyder EY (2002) 
Functional recovery following traumatic spinal cord injury mediated by a unique 
 
33
polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci U S A 99:3024-
3029. 
Teuber HL (1974) Recovery of function after lesions of the central nervous system: history 
and prospects. Neurosci Res Prog Bull 12:197-209. 
Thallmair M, Metz GA, Z'Graggen WJ, Raineteau O, Kartje GL, Schwab ME (1998) Neurite 
growth inhibitors restrict plasticity and functional recovery following corticospinal 
tract lesions. Nat Neurosci 1:124-131. 
Vanek P, Thallmair M, Schwab ME, Kapfhammer JP (1998) Increased lesion-induced 
sprouting of corticospinal fibres in the myelin-free rat spinal cord. Eur J Neurosci 
10:45-56. 
Verge VM, Gratto KA, Karchewski LA, Richardson PM (1996) Neurotrophins and nerve 
injury in the adult. Philos Trans R Soc Lond B Biol Sci 351:423-430. 
Wahle H (1990) [10-year follow-up of occupational integration of 50 patients with complete 
paraplegia]. Rehabilitation (Stuttg) 29:112-120. 
Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL, He Z (2002) 
Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite 
outgrowth. Nature 417:941-944. 
Wang X, Arcuino G, Takano T, Lin J, Peng WG, Wan P, Li P, Xu Q, Liu QS, Goldman SA, 
Nedergaard M (2004) P2X7 receptor inhibition improves recovery after spinal cord 
injury. Nat Med 10:821-827. 
Wernig A, Nanassy A, Muller S (1998) Maintenance of locomotor abilities following 
Laufband (treadmill) therapy in para- and tetraplegic persons: follow-up studies. 
Spinal Cord 36:744-749. 
Wernig A, Muller S, Nanassy A, Cagol E (1995) Laufband therapy based on 'rules of spinal 
locomotion' is effective in spinal cord injured persons. Eur J Neurosci 7:823-829. 
Wirz M, Colombo G, Dietz V (2001) Long term effects of locomotor training in spinal 
humans. J Neurol Neurosurg Psychiatry 71:93-96. 
Woolf CJ, Shortland P, Coggeshall RE (1992) Peripheral nerve injury triggers central 
sprouting of myelinated afferents. Nature 355:75-78. 
Woolf CJ, Reynolds ML, Molander C, O'Brien C, Lindsay RM, Benowitz LI (1990) The 
growth-associated protein GAP-43 appears in dorsal root ganglion cells and in the 
dorsal horn of the rat spinal cord following peripheral nerve injury. Neuroscience 
34:465-478. 
 
34
Xiao HS, Huang QH, Zhang FX, Bao L, Lu YJ, Guo C, Yang L, Huang WJ, Fu G, Xu SH, 
Cheng XP, Yan Q, Zhu ZD, Zhang X, Chen Z, Han ZG (2002) Identification of gene 
expression profile of dorsal root ganglion in the rat peripheral axotomy model of 
neuropathic pain. Proc Natl Acad Sci U S A 99:8360-8365. 
Xu XM, Chen A, Guenard V, Kleitman N, Bunge MB (1997) Bridging Schwann cell 
transplants promote axonal regeneration from both the rostral and caudal stumps of 
transected adult rat spinal cord. J Neurocytol 26:1-16. 
Zagrebelsky M, Buffo A, Skerra A, Schwab ME, Strata P, Rossi F (1998) Retrograde 
regulation of growth-associated gene expression in adult rat Purkinje cells by myelin-
associated neurite growth inhibitory proteins. J Neurosci 18:7912-7929. 
Z'Graggen WJ, Metz GA, Kartje GL, Thallmair M, Schwab ME (1998) Functional recovery 
and enhanced corticofugal plasticity after unilateral pyramidal tract lesion and 
blockade of myelin-associated neurite growth inhibitors in adult rats. J Neurosci 
18:4744-4757. 
Z'Graggen WJ, Fouad K, Raineteau O, Metz GA, Schwab ME, Kartje GL (2000) 
Compensatory sprouting and impulse rerouting after unilateral pyramidal tract lesion 
in neonatal rats. J Neurosci 20:6561-6569. 
Zheng B, Ho C, Li S, Keirstead H, Steward O, Tessier-Lavigne M (2003) Lack of enhanced 
spinal regeneration in Nogo-deficient mice. Neuron 38:213-224. 
Zhou L, Baumgartner BJ, Hill-Felberg SJ, McGowen LR, Shine HD (2003) Neurotrophin-3 
expressed in situ induces axonal plasticity in the adult injured spinal cord. J Neurosci 
23:1424-1431. 
 
 
35
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
 
 
 
 
 
 
 
It Takes More Than Two to Nogo 
 
 
 
 
Clifford J. Woolf and Stefan Bloechlinger 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Science, Vol. 297, pp. 1132-1134, 2002 
37
65
64
63
62
61
60
59
58
57
56
55
54
53
52
51
50
49
48
47
46
45
44
43
42
41
40
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
16 AUGUST 2002 VOL 297 SCIENCE www.sciencemag.org1132
tosecond pulse trains was reported by Pa-
padogiannis et al. (8). Last year, de Paul et
al. measured a train of 250-as pulses di-
rectly in the time domain (9).
Can such pulse trains be used for time-
resolved attosecond spectroscopy? Salières
et al. proposed in 1996 to use them for
monitoring processes that occur with the
period TL/2 of the train. Candidates for
such processes are harmonic generation it-
self or above threshold ionization (2), a
laser-induced ionization process in which
electrons absorb more photons than they
need to be released. All of these processes
can be described by “simple man’s mod-
els” (10). Unfortunately, today’s attosec-
ond pulses are not sufficiently intense to
realize time-resolved attosecond spec-
troscopy of these processes.
Although HHG is now an established
source for attosecond pulse trains, it has
one major limitation. Applications of time-
resolved spectroscopy to dynamics that do
not occur with the TL/2 period require sin-
gle isolated attosecond pulses. But there
may be a way around this problem. For
laser pulses shorter than 10 fs, the result-
ing individual harmonics fall below the
femtosecond limit. Because the laser pulse
lasts for only a few TL, the harmonics can-
not develop; instead, a soft x-ray attosec-
ond pulse should be generated.
Krausz and co-workers (11) generated
such an isolated attosecond x-ray pulse (λ
≈ 14 nm) by irradiating a very short laser
pulse (λ ≈ 750 nm) of ~5-fs duration on a
krypton gas sample, and filtering the out-
going radiation to a 5-eV range around 90
eV. They then irradiated the target krypton
sample simultaneously with the x-ray
pulse and a laser pulse of visible light of a
few laser cycles duration. The x-ray pulse
ionized the krypton atoms. The energy
spectrum of the photoelectrons depended
on the phase of the laser pulse at the mo-
ment of the electron’s detachment. When
the authors changed the relative delay be-
tween the laser and the soft x-ray pulse, a
modulation of the spectral width appeared,
allowing the duration of the x-ray pulse to
be estimated as ~650 as.
Krausz and co-workers now describe
(1) the first genuine application of isolated
attosecond pulses for time-resolved at-
tosecond spectroscopy. They study the ab-
sorption and emission of laser photons by
electronic wavepackets created by soft x-
ray radiation. Normally, the photoelectron
energy spreads as a result of the photon
absorption or emission (12). If, however,
the emitted electron wavepacket is tempo-
rally confined to a fraction of TL, its ener-
gy spectrum may be up- or down-shifted
by several laser photon energies without
broadening. The laser light can then
“steer” the electron wavepacket like a clas-
sical particle. The results of such “steer-
ing” depend on the timing of the attosec-
ond x-ray pulse relative to the absolute
phase of the laser (see the figure), offering
a simple, single-shot tool for time-resolved
attosecond spectroscopy.
Attophysics has moved from dream to
reality. One can expect fruitful applica-
tions of time-resolved attosecond spec-
troscopy to HHG or to above threshold
ionization processes induced by ultrashort
laser pulses, in which the absolute phase
of the laser pulse plays a crucial role (13).
Attosecond spectroscopy will provide di-
agnostics and perhaps new ways of con-
trolling these processes, in particular to
obtain better ways of short x-ray coherent
pulse generation.
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S C I E N C E ’ S C O M P A S S
T
he environment of the adult mam-
malian central nervous system (CNS)
is hostile to the growth of axons and
is a major contributor to the inability of in-
jured neurons to regen-
erate. Much of this in-
hibition is caused by
myelin, the insulating
lipid and protein mate-
rial that is wrapped around axons, ensuring
rapid transmission of electrical signals
along central nerve fibers. In the CNS,
myelin is produced by supporting glial cells
called oligodendrocytes. These cells also
make growth-inhibitory proteins that be-
come embedded within the myelin sheath.
Injured nerve fibers that make contact with
CNS myelin cease to regenerate. At least
three growth-inhibitory proteins have been
identified so far: Nogo-A, named for its in-
hibitory action on axonal growth; myelin-
associated glycoprotein (MAG); and oligo-
dendrocyte myelin glycoprotein (OMgp).
Although Nogo-A is known to bind to the
Nogo receptor (NgR), the receptors for
MAG and OMgp have remained elusive.
Now, in an extraordinary and unexpected
convergence reported by several groups in-
cluding Liu et al. (1) on page 1190 of this
issue, all three molecules appear to bind to
the same receptor, NgR (2–4). This discov-
ery opens up exciting new possibilities for
overcoming axonal growth inhibition, a vi-
tal step in neuronal regrowth after brain or
spinal cord injury.
During the development of the nervous
system and in neurons grown in culture,
the extension of axons from the cell body
begins with the formation of small pro-
cesses whose active tips have a specialized
structure called the axonal growth cone.
The growth cone interacts with the envi-
ronment to determine the direction and
rate of axon elongation. When the growth
cone contacts CNS myelin, its cytoskeletal
structure is altered, causing it to collapse
and resulting in cessation of axonal
growth. Nogo-A, MAG, and OMgp all
contribute to the inhibitory action of CNS
myelin on axonal growth and regeneration.  
Nogo-A, a member of the reticulon
family of proteins, has two inhibitory do-
mains: a cell surface domain called Nogo-
66 (5), and a long amino-terminal region
(6) (see the figure). The Nogo-66 domain
on the oligodendrocyte surface binds to
NgR, a leucine-rich repeat protein that is
attached to the extracellular surface of the
neuronal membrane by glycophos-
phatidylinositol (GPI) (4). The location of
the inhibitory amino-terminal domain of
Nogo-A may be cytoplasmic, although this
remains unclear (5, 6). If this is the case,
then the amino-terminal domain of Nogo-
A can inhibit axonal growth only when
myelin is disrupted by injury. No receptor
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for the Nogo-A amino-terminal domain
has been reported so far. Competitive inhi-
bition of the binding of Nogo-66 to NgR
by an antagonistic peptide, NEP1-40, over-
comes all of the inhibitory action of Nogo-
66 and much but not all of the inhibitory
action of CNS myelin on cultured neurons
(7). In vivo studies reveal similar effects on
regenerative neural growth after spinal
cord injury for both NEP1-40 (7) and IN-1,
a monoclonal antibody that recognizes No-
go-A (8). IN-1 antibody treatment also
causes rearrangement of intact fiber tracts,
which suggests that Nogo-A tonically sup-
presses neural growth in the adult CNS (9). 
MAG is a sialic acid–binding protein of
the SIGLEC (sialic acid–dependent im-
munoglobulin-like family member lectin)
group. It inhibits axonal growth in multiple
in vitro assays, although, surprisingly,
deleting the MAG gene does not promote
neuronal regeneration in mice (10). OMgp
is a GPI-anchored protein that was recently
found to potently inhibit neurite outgrowth
in culture (3). Both MAG and OMgp, like
Nogo-66, bind to NgR with high affinity
(1, 3). Although the NgR binding sites for
OMgp and Nogo-66 appear to overlap,
MAG and Nogo-66 bind to different sites
on NgR (1). Removal of NgR by cleaving
its GPI membrane anchor results in loss of
the growth-inhibitory action of all three
proteins. In contrast, introduction of exoge-
nous NgR into neurons that are unrespon-
sive to the growth-inhibitory proteins ren-
ders them responsive (1–4). NgR is there-
fore a promiscuous receptor binding to
multiple inhibitory myelin proteins, and it
appears to act as the major convergence
point on the surface of growth cones for
detecting many of the inhibitory influences
of CNS myelin. 
NgR has no transmembrane or intracy-
toplasmic domains and so must produce in-
hibition by binding to a membrane-bound
coreceptor that transduces the extracellular
signal and activates intracellular signaling
cascades that lead to the collapse of the
growth cone. Apparently, MAG binds not
only to NgR (1) but also to the ganglio-
sides GD1a and GT1b at least in some
(11), but not all (1), assays. This ganglio-
side action requires the low-affinity nonse-
lective neurotrophin receptor p75, which
forms a complex with GT1b that binds to
MAG (12). Thus, like Nogo-A, MAG
seems to have two independent receptors. 
Which signaling molecules downstream
of NgR or the GT1b/p75 complex transduce
the activation signals of Nogo-A, MAG, and
OMgp that result in growth cone collapse?
One possibility is Rho, a small membrane-
bound guanosine triphosphatase (GTPase).
Neurons expressing dominant-negative Rho,
which cannot transduce signals, are not re-
sponsive to the growth-inhibitory proper-
ties of MAG. Blocking Rho-GTPase ac-
tivity with the Clostridium botulinum en-
zyme C3 allows neurites to grow on
MAG substrates in vitro (13). Inhibition
of Rho-kinase (a downstream target of
Rho that interacts with the cytoskeleton)
overcomes GT1b-mediated blockade of
axonal elongation. In addition, cyclic
adenosine monophosphate (cAMP)
blocks MAG-induced inhibition by acti-
vating protein kinase A (PKA), which in-
activates Rho through phosphorylation
(14). Recently, it has been shown that
cAMP promotes neurite growth after spinal
cord injury in vivo (15, 16). 
The convergence of inhibitory influ-
ences at the level of both cell surface recep-
tors and intracellular signaling could be the
reason for the devastating suppression of
neuronal growth by CNS myelin after
spinal cord injury. This convergence could
explain the powerful independent effects of
Nogo-A, MAG, and OMgp, as well as the
modest increase in regeneration that is pro-
duced by blocking the activity of each indi-
vidual growth-inhibitory protein. Neuronal
regeneration is likely to be improved by tar-
geting NgR or Rho rather than by targeting
Nogo-A, MAG, or OMgp independently.
However, one major concern with this type
of treatment is that it may enable maladap-
tive sprouting and growth of noninjured
neurons, which could disrupt the highly or-
ganized connectivity of the CNS estab-
lished during development. Indeed, the
function of Nogo-A, MAG, or OMgp may
be related more to preservation of the
wiring of the CNS than to suppression of
neuronal regeneration. In any case, myelin
inhibition is not the only factor responsible
for the lack of regeneration. Astrocytes, an-
other type of CNS glial cell, also produce
inhibitory molecules, including tenascin
and chondroitin sulfate proteoglycan. In ad-
dition, overcoming inhibition is only half
the story; an increase in the intrinsic growth
capacity of the injured neurons is also re-
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Blocking axonal growth. Three growth-inhibitory molecules—MAG
(red), OMgp (orange), and the extracellular Nogo-66 domain of Nogo-A
(yellow)—are produced by oligodendrocytes in the CNS. These growth-inhibitory proteins become
embedded in the myelin sheath that surrounds axons, and they block the regeneration of nerve
fibers. They all bind to the same neuronal receptor NgR (pink), resulting in the activation of signaling
pathways that block axonal growth and induce growth cone collapse. NgR may require a coreceptor
to transduce intracellular signals via molecules such as the Rho GTPase, but this putative coreceptor
has not been identified. Activation of PKA leads to inactivation of Rho and prevents growth cone col-
lapse. In addition to binding to NgR, MAG also interacts with a complex between the gangliosides
GT1b and GD1a and the neurotrophin receptor p75, resulting in activation of Rho. The photomicro-
graphs depict primary adult dorsal root ganglion neurons grown either on a laminin substrate that is
permissive for growth (right) or on a CNS myelin substrate that prevents growth (left).
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quired (17). Nonetheless, the new reports
identifying the importance of NgR in pre-
venting neuronal regeneration represent a
big step forward in our understanding of the
molecular pathways that impede regenera-
tion in the CNS. The fact that these reports
provide a point of convergence—and there-
fore a potential reduction in the number of
interventions necessary to promote nerve
regeneration—is also good news.
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S C I E N C E ’ S C O M P A S S
O
nce every second, some-
where in the universe a mas-
sive star is disrupted in a su-
pernova explosion. Visible even at
cosmic distances, these stellar
catastrophes provide valuable infor-
mation about the history of star for-
mation in the universe. Ejecting
several solar masses of stellar de-
bris, they enrich the interstellar
medium with heavy elements from
millions of years of quiescent nu-
clear burning, and with radioactive
nuclei that are freshly synthesized
during the star’s violent death.
As brilliant as it may be, a super-
nova explosion is only a weak side
effect of a much more energetic
event. Theory suggests that as the
iron core of the exploding star col-
lapses to form a neutron star or
black hole, most of the gravitational
binding energy is carried away by
neutrinos. This prediction was con-
f irmed by the detection of two
dozen of the 1058 neutrinos from
Supernova 1987A in the under-
ground experiments of Kamiokande,
Irvine-Michigan-Brookhaven, and Baksan.
Typically, only 1% of the released energy
goes into kinetic energy of the ejecta, and
only a small fraction of this energy is con-
verted to electromagnetic radiation.
How is energy transferred from the col-
lapsing compact remnant to the matter that
gets ejected? Understanding this driving
force of the explosion is crucial for pre-
dicting remnant masses, explosion ener-
gies, and nucleosynthetic yields. It is thus
essential for establishing the theoretical
link between the properties of massive
stars and the observables of supernova ex-
plosions. Unfortunately, observations have
so far been unable to constrain the pro-
cesses that take place in the collapsed core
of a star.
Future measurement platforms may pro-
vide the required data by allowing thousands
of neutrinos and possibly gravitational waves
to be measured in a future supernova in our
Galaxy. But current knowledge is based
mainly on numerical simulations and analyt-
ic analysis. Despite more than 30 years of re-
search and increasingly detailed computer
models, there is still no satisfactory under-
standing of the start of the explosion. 
Stellar iron cores become gravitationally
unstable when energetic photons begin to
split iron-group nuclei into α particles and
free nucleons (protons and neutrons). At the
same time, electrons are captured by nuclei
and free protons, thereby reducing the pres-
sure even more and producing large numbers
of electron neutrinos. The latter can leave the
star unhindered until they get trapped as the
density grows. Within less than a second, the
inner part of the core collapses to nuclear
densities and then resists further compres-
sion due to the onset of nucleon degeneracy
and repulsive nuclear forces.
At this moment, a hydrodynamical
shock wave is launched and propagates
outward through the still supersonically in-
falling outer core. There is general agree-
ment that this shock cannot cause an ex-
plosion directly. It suffers from severe en-
ergy losses by photodisintegration of iron
nuclei and neutrino emission and therefore
stalls at a radius of 100 to 200 km.
But just fractions of a second later, the
situation has changed. The temperature be-
hind the standing shock has dropped so
much that energetic neutrinos, which leave
the hot, nascent neutron star in large flux-
es, are readily absorbed by free nucleons
in the postshock layer (the layer right be-
hind the supernova shock). If this energy
deposition is large enough, it can revive
the stalled shock and lead to a successful
“delayed” explosion (1, 2). Because the ul-
timate fate of the shock is determined by a
delicate rivalry between competing pro-
cesses, detailed computer models are
needed to answer the question of whether
the energy transfer to the shock by neutri-
nos is sufficient to lead to an explosion.
Wilson and Mayle (3) have successful-
ly simulated such neutrino-driven explo-
sions by making two assumptions, which
are, however, not generally accepted. They
assumed that convective mixing by neu-
tron-finger instabilities (4) in the neutron
star boosts neutrino emission. Moreover,
they considered high densities of pions
(strongly interacting elementary particles
that are built from a quark and an anti-
quark) in the neutron star medium to ob-
tain explosion energies in the observed
range (5). Both assumptions favor an ex-
plosion because the energy transfer by
neutrinos increases sensitively with higher
neutrino luminosities and energies.
But important other physics was missing
from the models of Wilson and colleagues,
as suggested by spectral observations of
P E R S P E C T I V E S : A S T R O N O M Y
The Secrets Behind Supernovae
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Three-dimensional supernova simulation. The perspec-
tive image shows convective mixing in a newly formed neu-
tron star. The mushroom-shaped structures are a result of
hydrodynamic instabilities (19). The colors represent differ-
ent fluid entropy values (blue, low; red, high) on a surface
of constant proton-to-neutron ratio. [Adapted from (19)]
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Neuronal Plasticity and Formation of
New Synaptic Contacts Follow Pyramidal
Lesions and Neutralization of Nogo-A:
A Light and Electron Microscopic Study
in the Pontine Nuclei of Adult Rats
STEFAN BLO¨CHLINGER, OLIVER WEINMANN, MARTIN E. SCHWAB, AND
MICHAELA THALLMAIR*
Brain Research Institute, University of Zurich and Swiss Federal Institute of Technology-
Zurich, CH-8057 Zurich, Switzerland
ABSTRACT
Regeneration and compensatory sprouting are limited after lesions in the mature mam-
malian central nervous system in contrast to the developing central nervous system (CNS).
After neutralization of the growth inhibitor Nogo-A, however, massive sprouting and rear-
rangements of fiber connections occurred after unilateral pyramidal tract lesions in adult
rats: Corticofugal fibers from the lesioned side crossed the midline of the brainstem and
innervated the contralateral basilar pontine nuclei. To determine whether these newly
sprouted fibers formed synaptic contacts, we analyzed the corticofugal fibers in the basilar
pontine nuclei contralateral to the lesion by light and electron microscopy 2 weeks after
pyramidotomy and treatment with the Nogo-A-inhibiting monoclonal antibody IN-1 (mAb
IN-1). The mAb IN-1, but not a control antibody, led to structural changes in the basilar pons
ipsilateral and contralateral to the lesion site. Fibers sprouted across the pontine midline and
terminated topographically. They established asymmetric synaptic contacts with the char-
acteristics of normal corticopontine terminals. These results show that adult CNS fibers are
able to sprout and to form new synaptic contacts after a lesion when a growth-permissive
microenvironment is provided. J. Comp. Neurol. 433:426–436, 2001. © 2001 Wiley-Liss, Inc.
Indexing terms: compensatory sprouting; neutralizing antibody; basilar pons; synapse; axotomy;
ultrastructure
Regenerative and compensatory plastic fiber growth af-
ter lesions is restricted to short distances in the adult
mammalian central nervous system (CNS). CNS tract le-
sions, therefore, lead to permanent functional impair-
ment. This limited anatomical and functional repair in the
mature CNS contrasts with the situation in the immature
CNS, in which regeneration and compensatory sprouting
of lesioned and unlesioned fibers can take place, and func-
tional deficits are small (Kennard, 1936, 1938; Kalil and
Reh, 1982; Kartje-Tillotson et al., 1986; Whishaw and
Kolb, 1988; Barth and Stanfield, 1990; Kuang and Kalil,
1990).
The importance of myelin and the myelin-associated
neurite growth inhibitor Nogo-A in preventing regenera-
tive and compensatory fiber growth in the adult mamma-
lian CNS has been well described (Caroni and Schwab,
1988a,b; Schwab et al., 1993; Kapfhammer, 1997; Chen et
al., 2000). After corticospinal tract (CST) lesions, neutral-
ization of Nogo-A by the monoclonal inhibitor-neutralizing
antibody 1 (mAb IN-1) enhanced long-distance regenera-
tion of adult corticospinal axons and recovery of locomotor
functions (Schnell and Schwab, 1990, 1993; Bregman et
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Histochemistry
Fourteen days after the BDA injections, all animals
were deeply anesthetized with pentobarbital (450 mg/kg,
i.p.; Nembutal, Abbott Laboratories, Cham, Switzerland)
and perfused transcardially with 100 ml of 0.5 M phos-
phate buffer (PB), pH 7.4, containing 0.9% NaCl
[phosphate-buffered saline (PBS), pH 7.4] and 50,000 UE
heparin (Liquemin; Roche, Reinach, Switzerland) followed
by 1,000 ml of the fixative (4% paraformaldehyde, 0.1%
glutaraldehyde, and 0.2% picric acid in 0.125 M PB, pH
7.4). The brains and spinal cords were removed and post-
fixed overnight in the same fixative at 4°C. The following
day, the pons was removed and embedded in a gelatin-
chicken albumin solution polymerized with 25% glutaral-
dehyde. The tissue was cut on a Vibratome into 50-mm-
thick cross sections that were collected in 0.1 M PB and
serially mounted on Superfrost-slides (Menzel-Gla¨ser,
Germany) according to the semifree-floating technique of
Herzog and Bro¨samle (1997). The sections were washed
and incubated overnight at 4°C with an avidin-biotin-
peroxidase complex (ABC; Elite kit; 1:100 in 0.1 M PB;
Vector Laboratories, Burlingame, CA). The next day, the
sections were washed three times for 10 minutes each in
0.1 M PB followed by a 5-minute wash in 0.05 M Tris
buffer, pH 8.0. The sections were reacted in 0.05% 3,39-
diaminobenzidine (DAB; Sigma, Buchs, Switzerland) and
0.003% H2O2 in 0.05 M Tris buffer, pH 8.0, for about 16
minutes. The process was stopped by washing in 0.1 M
PBS, pH 7.4. After three washes in 0.1 M PBS, the sec-
tions that were used for light microscopic evaluation were
air dried, dehydrated, and coverslipped with Eukitt (Kin-
dler, Freiburg, Germany).
Tissue processing for the electron
microscope
After the DAB reaction, sections were postfixed for 1
hour in 2.5% glutaraldehyde in 0.1 M cacodylate buffer,
pH 7.4, and subsequently washed in 0.1 M cacodylate
buffer. Regions with sprouted fibers were cut out with a
razor blade, postfixed for 20 minutes in 2% OsO4 in caco-
dylate buffer, and dehydrated in an ascending series of
ethanol. A contrast enhancement with 1% uranyl acetate
in 70% ethanol was integrated during the dehydration.
The tissue was flat embedded in Epon-Araldite (Serva,
Heidelberg, Germany). After polymerization at 60°C for
72 hours, the blocks were trimmed, and semithin sections
were examined for the presence of labeled axons. Ultra-
thin sections were cut on an LKB Ultratome (Bromma,
Sweden), collected on Pioloform-coated nickel grids (Stork
Veco B.V., Eerbeek, Netherlands), and contrasted with
Reynold’s lead-citrate solution. The sections were air dried
and examined in a Zeiss EM 902, electron microscope
(EM). Pictures were taken on Scientia EM films (Agfa-
Gevaert N.V., Brussels, Belgium) and with a Gatan 792
MultiScan Camera (Pleasanton, CA).
Neuroanatomical analysis
For the light microscopic neuroanatomical analysis,
three transverse sections of the basilar pons from each
animal were chosen. The most rostral section was taken at
the level where the lateral pontine nucleus appears. At an
intermediate pontine level, a section was chosen that con-
tained the ventromedial cluster of pontine neurons. The
level of the third, more caudally located section was de-
fined by the absence of the ventromedial cluster of pontine
neurons and by the appearance of decussating fibers of the
trapezoid body. The basilar pons and the cerebral pedun-
cle were outlined, and the midline was indicated using a
camera lucida attached to an Olympus microscope (Tokyo,
Japan). A vertical line parallel to the midline that divided
the basilar pons into a medial part and a lateral part was
drawn to anatomically separate the ventral pontine nu-
cleus from the medial pontine nucleus. This pontine divi-
sion line always crossed the medialmost part of the cere-
bral peduncle that served as an anatomical landmark and
was always located medial to the dense pontine innerva-
tion area seen in unilaterally pyramidotomized and IN-1
antibody-treated animals contralateral to the lesion site.
The distance between the midline and the pontine division
line was about one-third of the distance between the mid-
line and the lateral border of the cerebral peduncle (Fig.
1B). This division is similar to that proposed by Mihailoff
et al. (1981). The medial part contained the medial pon-
tine nucleus, and the lateral part contained most of the
ventral and lateral pontine nuclei (Fig. 1B).
The cross-sectioned area of the cerebral peduncle was
measured using the Neurolucida program (version 2.1;
MicroBrightField, Inc., Colchester, VT). Square areas of
29.4 mm 3 29.4 mm each were selected at three different
locations within the cerebral peduncle (Fig. 1B, asterisks),
all labeled corticofugal fibers in these three areas were
counted at 3400 magnification, and the total number of
labeled fibers per peduncle was calculated. To evaluate
the innervation pattern of the basilar pons contralateral
to the tracer injection, we evaluated three main features.
First, all labeled fibers crossing the midline were counted
in all three selected sections and divided by the total
number of labeled fibers of the cerebral peduncle for each
animal: This value was called the crossing fiber index.
Second, we counted all of the fibers that crossed the
medial-ventral pontine dividing line ventral to the cere-
bral peduncle. Third, the area with the highest density of
labeled fibers in the lateral part of the contralateral basi-
lar pons was selected, a square of 23.5 mm 3 23.5 mm was
placed in the center of this area, and all labeled axonal
structures crossing the borders of this square were
counted at a 31,000 magnification. All results of these
three evaluations were normalized for interanimal tracing
variability to the number of labeled cerebral peduncle
axons, as described above. To examine possible changes in
the ipsilateral innervation, the most lateral, ipsilateral
innervation field in the ventral pontine nucleus was cho-
sen, and, again, all labeled axonal structures crossing the
borders of a square (23.5 mm 3 23.5 mm) were counted at
31,000 magnification. In addition, all bouton-like swell-
ings of the fibers that were located within the square and
had a diameter greater than twice the fiber diameter were
counted to estimate the number of boutons formed per
fiber. The number of boutons on those fibers was divided
by the total number of fibers crossing the borders of the
square, resulting in a boutons per fiber index (boutons/
fiber index).
Statistical evaluation
To test the data for significant differences, the two-
sample t-test assuming unequal variances was used. All
data are presented as mean values 6 the standard error of
the mean (S.E.M.).
428 S. BLO¨CHLINGER ET AL.
45
Figure preparation
Images were assembled in Photoshop software (version
5.5; Adobe Systems, Mountain View, CA). Contrast and
brightness levels were adjusted when necessary.
RESULTS
Light microscopic studies
In all groups of animals, the tracer injection was cen-
tered in the forelimb area of the motor cortex. To account
for interanimal differences in tracing, the number of BDA-
positive neurites in the rostral cerebral peduncle was de-
termined for each rat, as described in Materials and Meth-
ods. The average number of labeled fibers was not
significantly different between the various experimental
groups: 9,285 6 589 axons in the anatomical control group
(n 5 3 rats; tracing only), 12,180 axons in the group of
lesioned animals (n 5 2 rats), 13,620 6 1,342 axons in the
lesioned group that was treated with anti-HRP antibody
(n 5 3 rats), and 11,147 6 1,176 axons in the group of
lesioned animals with IN-1 antibody treatment (n 5 6
rats).
Corticopontine innervation: Lesioned side
General innervation pattern. All experimental
groups showed an ipsilateral pontine innervation pattern,
as in several previous studies (Mihailoff et al., 1978;
Wiesendanger and Wiesendanger, 1982; Panto et al.,
1995; Z’Graggen et al., 1998). In animals with sharp and
exclusive forelimb motor cortex labeling, a single central
innervation field was observed at rostral pontine levels
within the ventral nucleus; more caudally, an additional
small innervation area in the medial part of the pons was
found. At caudal pontine levels, the innervation areas
were enlarged further, spreading over lateral, ventral,
and medial aspects of the basilar pons. These anatomical
findings were not influenced by the lesion location or the
type of antibody treatment.
Fiber and bouton density. Slight and variable
changes in the density of corticopontine fibers in the ven-
tral nucleus of the pons on the side of the CST lesion could
be observed after a unilateral CST lesion and antibody
treatment; however, this did not reach significance (trac-
ing only group: 0.38; n 5 3 rats; lesion only group: 0.72;
n 5 2 rats; lesion and anti-HRP antibody group: 0.58; n 5
3 rats; lesion and IN-1 antibody group: 0.68; n 5 6 rats).
The number of bouton-like structures along labeled fi-
bers innervating the ventral pontine nuclei was deter-
mined and expressed as the boutons/fiber index (see Ma-
terials and Methods). Whereas the lesioned animals
showed at best a trend for an increase, animals with CST
lesion and IN-1 antibody treatment showed a robust in-
crease of about 40% in the boutons/fiber index at all levels
of the pons (Fig. 2). Control antibody-treated rats never
showed such an effect.
Corticopontine fibers crossing the midline:
Innervation of the contralateral pons
General innervation pattern. In normal adult rats,
only a very minor group of corticopontine fibers projects to
the contralateral basilar pontine nuclei, mainly at mid-
pontine and caudal levels (Wiesendanger and Wiesendan-
ger, 1982; Panto et al., 1995; Z’Graggen et al., 1998).
Unilateral pyramidotomy combined with IN-1 antibody
treatment resulted in changes of the contralateral basilar
pontine nuclei innervation: An increased number of fibers
crossing the midline and a dense contralateral innerva-
tion of the ventral pontine nucleus were found (Fig. 3D–
F). This contralateral projection was distributed to the
mirror image location of the typical corticopontine projec-
tion zones. The density of this new contralateral innerva-
tion, however, was always less than the ipsilateral inner-
vation of the corresponding area. In the animals that
received unilateral pyramidotomy alone or with anti-HRP
antibody treatment, sprouting of some fibers that pro-
jected to the contralateral medial pontine nucleus and
innervation of a zone near the midline at a very low
density were observed (Fig. 3A–C). To investigate this
compensatory sprouting after a unilateral pyramidotomy
in more detail, we quantified the number of midline-
crossing corticopontine fibers, their spread to the ventral
pontine nucleus, and the density of the terminal plexus
formed.
Midline-crossing corticopontine fibers. Corticopon-
tine fibers from the lesioned side of the brain crossed the
midline either at the level of the ventral part of the pons
(white matter, where axons of pontine neurons cross to the
contralateral side before they ascend as mossy fibers to
Fig. 2. Quantification of the innervation density in the most lat-
eral corticopontine termination field in the ventral nucleus ipsilateral
to the tracer injection and lesion. A: Animals that underwent a uni-
lateral pyramidal lesion and received the monoclonal antibody (mAb)
IN-1 showed a 40% higher boutons per fiber index than the control
groups. B: Rostrocaudal distribution of the boutons per fiber index.
The significant increase in bouton-like structures in animals in the
lesion and mAb IN-1 treatment group was found at all pontine levels.
Asterisks indicate significance: single asterisk, P , 0.05; double as-
terisks, P , 0.01; triple asterisks, P , 0.001.
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the cerebellum) or directly between the basilar pontine
nuclei (gray matter). Normal animals, rats with CST le-
sion alone, or lesioned, control antibody-treated rats had
only very few corticopontine fibers crossing the midline
(Figs. 3C, 5A,B). In the pons of lesioned animals that were
treated with IN-1, however, about three times more cor-
ticopontine fibers crossing the midline were found (Figs.
3E, 4C, 5A). Similar to what was seen in normal rats, the
number of crossing fibers increased from rostral to caudal
pontine levels (Fig. 5B). The few crossing fibers in the
lesioned, anti-HRP antibody-treated and the lesion-only
group ended in an area close to the midline. All labeled
fibers in this area were very thin, forming a diffuse inner-
vation field of very low density. In lesioned, IN-1-treated
animals, this innervation area also was present, but many
labeled fibers projected straight and laterally through this
area to arborize and terminate in more lateral regions
(ventral pontine nucleus; Fig. 3F).
Crossed fiber projection to the lateral part of the
pons. To examine which parts of the contralateral pons
were reached by the midline-crossing fibers, a vertical line
was drawn separating the medial part from the more
lateral parts of the nuclear complex (Fig. 1B). All labeled
fibers crossing this pontine division line were counted at
the three pontine levels. Fibers crossing this line reached
at least the ventral pontine nucleus and also may project
to more lateral regions. In normal animals, only very few
fibers were seen to cross the medial-lateral division line,
even at most caudal pontine levels. Pyramidotomy, espe-
cially when combined with a control antibody-secreting
hybridoma transplant, showed a small increase in the
number of laterally growing fibers (Fig. 5C). The lesioned,
IN-1 antibody-treated animals had about twice as many
fibers crossing the medial-lateral division line; this in-
crease was significant at all pontine levels and increased
from rostral levels to caudal levels (Fig. 5C,D).
Innervation density of contralateral pontine nuclei.
In each examined cross section, the area in the lateral part
of the pons that contained the densest innervation by
crossing corticopontine fibers was evaluated quantita-
tively for fiber density (see Materials and Methods, above).
There were no significant differences between normal an-
imals, pyramidotomy alone animals, and lesioned, control
(anti-HRP) antibody-treated rats at rostral levels (Fig.
5F). At midpontine and caudal levels, the lesioned control
groups had slightly higher fiber densities (Fig. 5F). The
innervation index of the lesioned, IN-1 antibody-treated
group, in which the highest labeling density was always
located in the lateral part of the ventral pontine nucleus,
was at least two times higher than in the other groups
(Fig. 5E). An example of the innervation density in a
lesioned, IN-1 antibody-treated animal is shown in Figure
4A (ipsilateral to the lesion) and Figure 4B (contralateral
to the lesion). This increase of innervation density showed
a rostral-to-caudal gradient, similar to the number of
midline-crossing fibers (Fig. 5F).
Ultrastructural studies
General findings. At the ultrastructural level, BDA
labeling was characterized by the presence of an electron-
dense DAB reaction product filling the entire cytoplasm of
the labeled axons or terminals (Fig. 6). Cell organelles,
such as mitochondria, endoplasmic reticulum, and synap-
tic vesicles, remained free of label. Ultrathin sections of
the pons showed the known distribution of fibers and
neuronal somata (Mihailoff et al., 1981). At the ventral
border, bundles of strongly myelinated fibers, the fibrae
transversae, formed the efferent system of the pons that
projects as mossy fibers to the contralateral cerebellar
hemisphere. Between the cerebral peduncle and this ven-
tral white matter, clusters of pontine neurons alternated
with bundles of fibers, most of them myelinated. Within
the clusters of these pontine neurons, unmyelinated ax-
onal and dendritic profiles were present. Synaptic profiles
that were found in the pons were asymmetric and con-
tained round vesicles of various sizes.
Labeled axonal and presynaptic structures. The
lateral part of the ventral pontine nuclei contralateral to
the pyramidal lesion and the tracer injection was analyzed
for labeled axons and synapses in mAb IN-1-treated ani-
mals. Most of these labeled, crossed corticopontine axons
were of small diameter (from 0.04 mm up to 0.29 mm; most
were between 0.15 mm and 0.25 mm if no mitochondrial
profiles were present, whereas neurites containing mito-
chondria had diameters up to 0.53 mm). It is noteworthy
that none of the labeled axons was myelinated (consistent-
ly in five animals; approximately ten labeled fibers per
section), in contrast to many labeled myelinated axons in
pontine innervation fields ipsilateral to the tracer injec-
tion (data not shown). Vesicle-like structures that were
seen in the labeled axons often were round and had the
same size as the vesicles seen in labeled synapses.
Labeled synapses, frequently in the vicinity of labeled
axonal profiles, showed a high variability in size and often
very irregular shapes (Fig. 6). Most of them were large,
and they contained up to six mitochondrial profiles. Com-
pared with neighboring, unlabeled presynaptic structures,
the number of mitochondria in these labeled, presumably
newly formed synapses appeared to be increased. The
synaptic vesicles were homogeneous in size (25–40mm)
and round in shape. All examined labeled boutons formed
asymmetric synaptic contacts on dendritic processes, often
on dendritic spines (Fig. 6). Axosomatic contacts on basi-
lar pontine neurons were not found. Labeled synapses
were found almost exclusively in lesioned, mAb IN-1-
treated animals; about ten labeled fibers and three or four
synapses were found per EM section (0.5 mm 3 0.5 mm) of
the lateral pons of mAb IN-1-treated animals (n 5 5 rats).
DISCUSSION
In this report, we provide evidence for lesion-induced
sprouting of corticopontine fibers after mAb IN-1 treat-
ment in adult rats. The fibers sprouted across the pontine
midline and established new synapses contralateral to the
lesion and tracer injection site. The novel synapses
showed the same ultrastructural characteristics that are
seen in normal corticopontine synaptic endings.
A unilateral pyramidotomy in adult mammals leads to
long-lasting functional impairments of fine motor control
of the forelimbs, as shown in previous studies. No func-
tional recovery of precision movements and little or no
anatomical plasticity were found after such lesions in
mature animals (Kuang and Kalil, 1990). Masking of the
myelin-associated neurite growth inhibitor Nogo-A by
mAb IN-1 resulted in major structural rearrangements
and an almost complete functional recovery in several
behavioral tasks (Thallmair et al., 1998; Z’Graggen et al.,
1998).
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cally (Mihailoff et al., 1978; Wiesendanger and Wiesend-
anger, 1982; Panto et al., 1995). Animals that showed such
structural plasticity in the pons and sprouting in the cer-
vical spinal cord recovered almost completely in a food-
pellet reaching paradigm, a behavioral task that required
fine motor control (Z’Graggen et al., 1998).
The new BDA-labeled axons and terminals contralat-
eral to the lesion and tracer injection site most likely
represent sprouted corticofugal fibers; such fibers were
virtually absent in normal and lesioned control animals.
However, we cannot exclude the possibility that some of
the labeled fibers and boutons in the contralateral basilar
pontine nuclei may represent the normal crossed cortico-
pontine projection, which is very small (Wiesendanger and
Wiesendanger, 1982; Panto et al., 1995; Z’Graggen et al.,
1998). In addition, we showed fibers and boutons in re-
gions of the pons that typically do not receive the normal
crossed projection. Thus, we suggest that normal crossed
projections play a minor role in the expansion of the con-
tralateral terminal fields after lesion and IN-1 antibody
treatment. The increase of midline-crossing fibers in the
pons may be derived from fibers that are redirected to the
contralateral pons or from neurites that formed new col-
laterals to innervate the contralateral pontine nuclei.
Fig. 5. Three main features were evaluated to quantify the inner-
vation of the basilar pons contralateral to the lesion and the tracer
injection site. A: Quantification of pontine midline-crossing fibers. In
mAb IN-1-treated animals, a three-fold increase of midline-crossing
fibers was found, whereas the anti-HRP-treated and lesion-only ani-
mals showed values similar to those found in normal rats (tracing
only). B: Like the normal animals, the number of midline-crossing
fibers increased from rostral to caudal pontine levels. At every pontine
level, the IN-1 group showed significantly more midline-crossing fi-
bers than the control groups. C: To determine which parts of the
contralateral pons were reached by the midline-crossing fibers, all
axons crossing the pontine division line were counted. The unilateral
pyramidal lesion, especially when combined with an anti-HRP anti-
body treatment, resulted in a small increase in the number of laterally
growing fibers. The lesioned, IN-1 antibody-treated animals, however,
showed almost twice as many fibers crossing this lateral line. D: The
number of fibers crossing the pontine division line increased from
rostral to caudal, similar to the number of midline-crossing fibers.
This increase was significant for the mAb IN-1-treated and anti-HRP-
treated animals at all pontine levels. E: Pyramidotomy in combina-
tion with IN-1 antibody treatment led to an at least two-fold increase
in the innervation index, whereas there were no significant differ-
ences between the control groups. F: The innervation index was
significantly enhanced in mAb IN-1-treated animals at all pontine
levels, with a slight trend toward higher values from rostral to caudal.
Asterisks indicate significance: single asterisk, P , 0.05; double as-
terisks, P , 0.01; triple asterisks, P , 0.001 (t test).
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The new midline-crossing fibers terminated topograph-
ically in the contralateral basilar pontine nuclei, and the
EM results showed that the synapses formed by these
midline-crossing fibers had the typical structural charac-
teristics of corticopontine boutons (Mihailoff and McArdle,
1981). The synaptic contacts were asymmetric (Gray’s
type I; Gray, 1959) and the boutons contained round ves-
icles (rat: Mihailoff and McArdle, 1981; cat: Holla¨nder et
al., 1969). Considering these structural characteristics, we
suggest that the new synapses belong to Mihailoff and
McArdle’s (1981) category 1 of pontine terminal endings.
The finding of new synapses with the typical characteris-
tics of corticopontine presynaptic profiles in the contralat-
eral pons after a unilateral lesion corroborates earlier EM
reports in which axonal sprouting in the corticopontine
system was described after neonatal cortical lesions (Le-
ong, 1976; Mihailoff and Castro, 1981). The new synapses
terminated exclusively on dendrites, as described previ-
ously for normal synaptic contacts of the same category
(Brodal, 1968; Holla¨nder et al., 1969; Mihailoff and
McArdle, 1981).
Neutralization of the myelin-associated neurite growth
inhibitor Nogo-A also resulted in some lesion-induced
changes in the ipsilateral pons. In the ipsilateral medial
pontine nuclei, the fiber density showed a small and vari-
able increase after lesion alone and in combination with
antibody treatment. A similar weak increase in fiber den-
sity has been found in the ipsilateral pons after a unilat-
eral pyramidotomy in the neonatal and adult rat in a
previous report (Z’Graggen et al., 2000). In our study,
however, we found a significantly enhanced bouton/fiber
index in the ipsilateral pons in mAb IN-1-treated animals
after a unilateral pyramidal lesion, reflecting sprouting
and possibly reinforcement of ipsilateral corticopontine
connections.
The lesion-induced changes of the corticopontine inner-
vation described here probably are due to and influenced
by a variety of factors in addition to the neutralization of
the neurite growth inhibitor Nogo-A. Functional imbal-
ance of the motor and sensory systems caused by the
lesion may lead to an up-regulation of growth-promoting,
guidance, and survival factors (Wizenmann et al., 1993;
Thoenen, 1995). The nature of these factors in the corti-
copontine system is not known at the moment. The infor-
mation for the formation of new, characteristic corticopon-
tine synapses also must be present or reexpressed in these
adult animals.
The anatomical results presented here were obtained 2
weeks after the lesion and implantation of the antibody-
secreting hybridoma cells. Thus, the structural changes
occurred rapidly, and, most likely, these rearrangements
remain stable over time, as shown in a previous study
from our laboratory (Z’Graggen et al., 1998). The precise
time course of sprouting, synapse formation, and possibly
also retraction phenomena is not known. Corticopontine
fibers may be rerouted or may give rise to new collaterals.
When new synapses are formed, a phase of activity-driven
refinement may follow and, finally, the elimination of ex-
uberant or wrong connections. Some of the fibers termi-
nating in the pons are collaterals of corticospinal fibers
(Ugolini and Kuypers, 1986; Akintunde and Buxton,
1992). The transection of these fibers by the pyramidal
lesion may lead to a compensatory sprouting across the
pontine midline (Sabel and Schneider, 1988; “pruning ef-
fect”). In addition, the unilateral pyramidal lesion dener-
vates half of the spinal cord and the dorsal column nuclei
ipsilateral to the lesion, which may cause a functional
imbalance of the motor and sensory systems. Activity-
driven up-regulation of neurotrophic or growth-promoting
factors may induce the formation of new collaterals, en-
hanced terminal arborizations, and new synapses in the
pontine nuclei.
Recently, a new additional role of Nogo-A has been
found (Zagrebelsky et al., 1998): Myelin-associated neu-
rite growth inhibitors seem to actively suppress the ex-
pression of growth-associated genes in adult central neu-
rons. Thus, the application of neutralizing antibodies not
only may provide a growth-permissive microenvironment
by locally masking the myelin-associated neurite growth
inhibitor Nogo-A but also may lead to an up-regulation of
growth-associated gene expression in the cell body.
In a previous study, we showed that a very high degree
of functional recovery takes place after unilateral pyra-
midotomy and treatment with mAb IN-1 (Z’Graggen et al.,
1998). The sprouted fibers and the new synapses described
here in the pons, as well as other plastic rearrangements
in the brainstem, brain, and spinal cord (Thallmair et al.,
1998), probably contribute and collaborate to restore fine
movements in these unilaterally lesioned, anti-Nogo-A
antibody-treated adult animals.
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Introduction 
 
 
The ability of neurite extension and axonal growth within the nervous system of 
mammals varies strongly with age and between the central and peripheral nervous systems.  
In the embryonic and early postnatal stage the nervous system’s plasticity is enormous, 
serving to build up the appropriate connections among nerve cells as well as their non-
neuronal targets. In the early postnatal stage, the central nervous system (CNS) can restore 
damage to a high degree and, in parallel with maturation of the CNS, its growth capacity is 
reduced after birth prohibiting uncontrolled axonal growth in the adult (Cai et al., 2001; 
Kapfhammer & Schwab, 1994). This lack of axonal growth capacity becomes apparent after 
injuries to the brain or spinal cord because the loss in function cannot be restored by 
regeneration of nerve cells and their lost interactions (Schwab, 2004; Schwab & Bartholdi, 
1996). In comparison to the adult CNS, the peripheral nervous system (PNS) allows neuronal 
re-growth after nerve damage, resulting in partial target re-innervation and recovery of lost 
function (Bray et al., 1981; Rhodes & Fawcett, 2004; Schmitt et al., 2003; Schwab & 
Bartholdi, 1996). 
It is believed that in order to grow successfully, neurons require a favorable 
environment and the activation of a growth program to do so. Myelin-associated molecules 
(Nogo, MAG, OMgp) which strongly inhibit axonal growth in vitro and in vivo are 
responsible for a great proportion of regenerative failure in the adult CNS (Chen et al., 2000; 
GrandPré et al., 2000; McKerracher et al., 1994; Schwab, 2004; Wang et al., 2002). Besides 
inhibitory extracellular cues, the growth capacity of a neuron is crucial, determined by its 
transcriptional and translational apparatus supplying the cell with structural elements and 
membrane- and intracellular receptors (Chong et al., 1996; Neumann & Woolf, 1999; 
Richardson & Issa, 1984; Schreyer & Skene, 1993). It is known that embryonic neurons 
possess a far greater intrinsic potential for regenerative axonal growth after injury. Therefore, 
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regenerative axonal growth in the adult nervous system has been attributed to the 
manifestation of an embryonic-like neuronal phenotype (Cai et al., 2001; Chong et al., 1996; 
Neumann & Woolf, 1999). A number of intrinsic neuronal molecules have been identified as 
favorable for neuronal growth, for instance those belonging to the GAP-43-like family (for 
review see (Bomze et al., 2001; Caroni, 2001; Skene, 1989). GAP-43 (growth-associated 
protein 43) is widely seen as a typical growth-related protein because of its high expression 
during embryonic and early postnatal development, its strong induction in dorsal root 
ganglion (DRG) neurons after injury to the peripheral nerve and its correlation to a growing 
phenotype (Aigner et al., 1995; Aigner & Caroni, 1993; Chong et al., 1994; Frey et al., 2000; 
Schreyer & Skene, 1991). Other molecules have been identified and suggested to contribute to 
axonal growth. Their expression patterns during development and after neural injury in the 
adult are often not well characterized. It is not clear for most of these genes whether their 
expression pattern mimics that of GAP-43 and therefore supports the theory of the 
recapitulation of a developmental transcriptional program after nerve injury in the adult. 
In our study we performed microarray analysis on rat DRG and found more than 120 
differentially regulated genes during development and following injury. Based on this, we 
profile the expression of five genes during development and after injury to the peripheral and 
the central nervous system and compare them to the expression of GAP-43 to test the 
hypotheses that growth-associated genes are regulated in primary sensory neurons after 
peripheral axotomy in order to mount a growing phenotype seen during the development of 
the nervous system. We show that genes regulated after injury do not necessarily recapitulate 
developmental expression and that some of the examined genes are, in contrast to GAP-43, 
also regulated by axotomy of their central axons.  
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Methods 
 
Surgery and tissue collection 
Adult male Sprague Dawley rats (200-250g) and rat embryos were used in this study 
and all procedures were performed in accordance with the Massachusetts General Hospital 
Animal Research regulations. For surgery, the animals were anesthetized with isoflurane 
(inhalation induction, 4%; maintenance, 2.5%) and underwent either a unilateral sciatic nerve 
transection (SNT), a unilateral dorsal rhizotomy (DR) or a bilateral lesion of the dorsal 
funiculus (DCL) including the ascending dorsal column fibers and the dorsal part of the 
corticospinal tract (dCST) at thoracic level T6/7. For DR and DCL the spinal cord was 
exposed by either a hemi- or total laminectomy. The dorsal roots of L4, L5 and L6 (DR) or 
the dorsal funiculus (DCL), were cut using fine micro-scissors. For SNT, the left sciatic nerve 
was exposed at midthigh, ligated and transected distal to the ligation. The wound was 
carefully sutured and animals were kept alive for the indicated numbers of days. Animals 
were terminally anesthetized by CO2, decapitated and exsanguinated. The sciatic nerve was 
exposed and traced to L4 and L5 DRGs. L4 and L5 DRGs were bilaterally removed, followed 
by dissection of the spinal cord. The dissection of the brain was simultaneously performed by 
a second person, in order to quickly collect fresh tissue. DRGs and the area of the cerebral 
cortex including the sensory-motor hindlimb area were removed bilaterally and immediately 
frozen in tubes on dry ice or, for in situ hybridization, embedded in OCT compound (Tissue 
Tek) and frozen on dry ice. Tissue was stored at –80°C until use.  
 
Microarray Analysis 
Total RNA was extracted from homogenized DRG samples using acid phenol 
extraction (TRIzol reagent, Gibco-BRL). RNA concentration was evaluated by A260 
measurement, and quality was assessed by electrophoresis on a 1.5% agarose gel. Each RNA 
 
58
sample used for hybridization of each array was extracted from rat L4 and L5 DRGs (10 
ganglia pooled from 5 animals, per sample). 
Affymetrix rat genome U34A oligonucleotide microarrays, representing 8799 known 
transcripts and expressed sequence tags (ESTs), were used (Santa Clara, CA 
http://www.affymetrix.com). Oligonucleotides are arranged in pairs corresponding to different 
regions of the target mRNA with multiple probe pairs. Each probe pair consists of a 25 
nucleotide perfect match (PM) to the target region coupled with a 25-mer with a single 
mismatch (MM) at the 13th nucleotide. Transcript abundance is estimated by analysis of signal 
intensity of the PM/MM pairs. The arrays are hybridized with biotin-labeled cRNA, prepared 
as per standard Affymetrix protocol. Briefly, total RNA (8 µg) from DRGs was reverse 
transcribed using an oligo-dT primer coupled to a T7 RNA polymerase binding site. Double-
stranded cDNA was made and biotinylated-cRNA synthesized using T7 polymerase. The 
cRNA was hybridized for 16 hours to an array, followed by binding with a streptavidin-
conjugated fluorescent marker, and then incubated with a polyclonal anti-streptavidin 
antibody coupled to phycoerythrin as an amplification step. Following washing, the chips 
were scanned with a Hewlett-Packard GeneArray laser scanner and data analyzed using 
GeneChip software. External standards were included to control for hybridization efficiency 
and sensitivity. 
Hybridization levels for each species of mRNA detected on the arrays are expressed 
by intensity (signal) and as present (P), marginal (M) or absent (A) calls, calculated by 
Affymetrix software (MAS 5.0, α1 = 0.04 α2 = 0.06). To normalize the array data standard 
Affymetrix protocols were used, each array was scaled to a target signal of 2500 across all 
probe sets (MAS 5.0). Genes with A calls or intensity levels < 1000 at every time-point 
examined were excluded. Genes included into table 1 or 2 show a fold difference ≥ 1.4 or ≤ -
1.4 at any one of the investigated experimental conditions, the result obtained for the 3d SNT 
time-point corresponds to the previously published triplicate chip analysis for that time-point 
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(cut-off ≥ 1.4, ≤ -1.4 fold change respectively) and their developmental expression profile and 
mRNA expression in response to injury has not been well described yet (Costigan et al., 
2002). 
 
Isotopic In Situ Hybridization 
 In situ hybridization was carried out as described previously (Karchewski et al., 1999) 
using 48 base pair oligonucleotide probes complementary to and selective for the following 
mRNAs: GAP-43 (Accession #M16228), α-internexin (Accession #M73049), glypican-1 
(Accession # NM_030828), α-fodrin (Accession #AF084186), osteopontin (Accession 
#M146656), α7-integrin (Accession #X65036). Oligonucleotide probes (80 ng) were labeled 
using terminal transferase with either α-[35S]dATP or α-[33P]dATP (NEN, MA, USA) and 
purified through a spin column (Qiagen, CA, USA). Specific activities ranged from 2.0-5.2 x 
106 cpm/ng oligonucleotide.  
Slides were hybridized at 43°C for 14-18 hours in a buffer containing 50% formamide, 
4x SSC, 1x Denhardt’s solution, 1% sarcosyl, 0.02 M phosphate buffer (pH 7.0), 10% dextran 
sulphate, 500 mg/ml heat-denatured salmon sperm, 200 mM DTT and 107 cpm/ml of 
radiolabeled oligonucleotide probe. Slides were washed 4 x 15 minutes in 1x SSC at 55°C, 
brought to room temperature, dipped twice in dH2O, dehydrated in ascending alcohols, and 
air-dried. The hybridization stringency conditions used require homologies greater than 90% 
for retention of the transcripts following the washes (Dagerlind et al., 1992). Slides were 
stored at 4°C until processed by emulsion autoradiography. 
The specificity of hybridization signal for each probe was ascertained by hybridization 
of adjacent sections with labeled probe, labeled probe with a 1000-fold excess of cold probe, 
or labeled probe with a 1000-fold excess of another, dissimilar cold probe of the same length 
and similar G-C content. 
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Emulsion Autoradiography 
Under safelight conditions, slides were dipped in NTB-2 nuclear track emulsion 
(Kodak) (1:1 in dH2O) dried and stored in lightproof slide boxes with desiccant at 4°C. The 
sections were exposed for 1-12 weeks before being developed and fixed.  For viewing under 
darkfield conditions using a fiber-optic darkfield stage adapter (MVI, MA, USA), slides were 
left unstained and coverslipped using glycerol. For viewing under the brightfield microscope, 
slides were counterstained with 0.5% Toluidine blue (pH 4-4.5), differentiated and 
coverslipped using Permount (Fisher). Photographs were taken using a Spot camera 
(Diagnostic Instruments Inc., MVI, MA, USA).  
 
Slot blotting 
Slot blots were produced as described previously (Costigan et al., 2002). Briefly total 
RNA (1.25 µg) was directly transferred to Hybond N+ nylon membrane under vacuum. The 
slot blots were produced in batches of six. Each tissue type RNA sample was applied from a 
master mix ensuring equal loading across all of the blots. Gene specific probes between 200-
500 bp were produced using RT-PCR. PCR was performed on cDNA reverse transcribed 
from total RNA, extracted from lumbar DRGs, using poly-dT as a primer. Primers were 
designed using the Primer3 software (http://www-genome.wi.mit.edu/) from the 1000 most 3' 
nucleotides within each accession sequence.  These fragments were subsequently cloned into 
the PCRII vector (TA cloning Kit, Invitrogen) and the identity of each was confirmed by 
sequencing. These cDNAs were gel-purified and used to produce 32P-labeled cDNA probes 
(Prime-It kit, Stratagene). 
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Results 
 
Growth-related genes have distinct expression patterns in the DRG of the developing CNS. 
Chip analysis from lumbar DRG reveals the characteristic expression of growth-
associated protein-43 (GAP-43), a crucial protein determining axonal growth processes, 
during CNS development (Donovan et al., 2002; Frey et al., 2000; Karimi-Abdolrezaee et al., 
2002). High levels of GAP-43 mRNA are detected in DRG at time-points E15, E18, E20 until 
P0 followed by a significant decrease in GAP-43 expression in the adult animal (2.4 fold 
change P0 vs. adult, Figure 1A). α-internexin, the earliest intermediate filament expressed 
during embryonic development (Ching & Liem, 1991; Chiu et al., 1989; Fliegner et al., 1990; 
Kaplan et al., 1990; Pachter & Liem, 1985), shares the property of high expression in DRG 
early in development at E15 and declining levels of detectable mRNA towards adulthood 
(Figure 1B). In contrast to GAP-43 mRNA levels of α-internexin rapidly decrease after E15 
and show a slower reduction between E18 and P0. GAP-43 and α-internexin represent genes 
with strong expression during embryonic development of the CNS when neural cell 
migration, proliferation and differentiation, as well as neuritogenesis occur and both are genes 
with moderate to low levels of mRNA in the adult DRG. Although α-internexin was attributed 
an absent (A) call in the adult DRG, in-situ hybridization and slot-blot analysis clearly detect 
α-internexin mRNA in the adult DRG (Figure 1B, 2B and 3B). 
In general we have observed two other major developmental expression patterns for 
growth-related genes in the rat lumbar DRG. Glypican-1, a glycosyl phosphatidyl inositol 
(GPI) – anchored heparan sulphate proteoglycan (for reviews see Bandtlow & Zimmermann, 
2000; Fransson, 2003), and α-fodrin, a member of the spectrin superfamily of 
submembranous cytoskeletal proteins (Hartwig, 1995; Ursitti et al., 2001), are both expressed 
at high levels in the embryo and expression levels remain stable in the adult DRG, revealing 
relatively constant gene expression in the developing as well as in the mature rat DRG (Figure 
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1C and 1D). Osteopontin, a glycoprotein with diverse functions in cell adhesion and cellular 
activation, chemoattraction and immunomodulation (for review see (Denhardt & Guo, 1993; 
Denhardt et al., 2001; Wang et al., 1998), is detected at very low levels in E15 and E18 DRG 
(absent (A) call by Affymetrix). Slightly higher levels of mRNA are detected by chip analysis 
in the DRG at E20 and P0 (present (P) call, Figure 1E). In the adult rat DRG, osteopontin 
mRNA expression is increased 15.3 fold compared to P0 (Figure 1E). The α7-integrin subunit 
of the laminin-1/-2 receptive molecule α7/β1-integrin (Hammarberg et al., 2000; Yao et al., 
1996) shows moderate levels of mRNA at embryonic stages, with a substantial increase of 
mRNA levels in the adult DRG (adult vs. P0 2.4 fold increase, Figure 1F). Together, these 
two genes show highest mRNA expression in the adult DRG, whereas lower levels of mRNA 
are detected in the embryo.  
We find 116 genes that showed significant developmental regulation in DRGs falling 
into different categories including genes coding for structural and signaling molecules as well 
as proteins involved in cell metabolism (Table 1). Many ribosomal components are found to 
be strongly expressed early in development showing generally slightly lower but still elevated 
expression levels around P0 compared to adult (Table 2). 
 
Sciatic nerve transection (SNT) dynamically up- or down-regulates neural growth-related 
genes in adult DRG neurons.  
Affymetrix gene chip analysis performed with mRNA from adult lumbar L4 and L5 
DRG compares the expression of the above mentioned genes between uninjured animals and 
animals that underwent a SNT either 3 days, 7 days or 21 days prior to mRNA preparation. 
SNT is known to cut approximately 60% of the axons of L4 and L5 lumbar DRG neurons. 
Here we show that GAP-43 mRNA expression is induced as early as 3 days post-SNT (2.6 
fold increase) and mRNA levels increase over the whole time-course examined (21d SNT vs. 
adult 3.3 fold, Figure 1A). α-internexin, dramatically down-regulated during development, 
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shows a tendency of increasing mRNA levels reaching approximately P0 expression levels 21 
days post-injury (Figure 1B). Glypican-1 appears up-regulated after SNT over the whole time-
course investigated, revealing peak mRNA levels 7 days post-SNT (7d 1.9 fold, 21d 1.5 fold, 
Figure 1C). α-fodrin mRNA stays unchanged after SNT over the whole period examined 
(Figure 1D). Osteopontin and α7-integrin share a common response in mRNA expression to 
SNT, as well for the time-course of induced changes as for absolute intensity levels. Both 
genes are quickly and massively induced, mRNA expression peaks at day 3 post-SNT (3d vs. 
uninjured, osteopontin 1.8 fold, α7-integrin 1.9 fold) and levels stay slightly above uninjured 
21 days post-injury (Figure 1E and 1F).  
Using isotopic in situ hybridization we have investigated the localization of gene 
expression and verified changes seen in the gene chip analysis (Figure 1 and 2). GAP-43 is 
expressed by sensory DRG neurons in the non-injured animal. Its expression is strongly 
induced 3 days post-SNT and remains mainly neuronal (Figure 2). For α-internexin, mRNA is 
localized to neurons and no obvious regulation 3 days after SNT is found, probably due to the 
low abundancy of mRNA in the DRG, a limiting factor for visualization by isotopic in situ 
hybridization (Figure 2). As previously shown (Bloechlinger et al., 2004), glypican-1 mRNA 
is predominantly and clearly induced in primary sensory neurons 3 days following SNT 
compared to non-injured (Figure 2). α-fodrin mRNA is localized almost exclusively in 
neurons and is highly abundant in the non-injured DRG as well as 3 days post-SNT where no 
change in expression is detected (Figure 2). High levels of osteopontin mRNA are already 
present in the non-injured condition, but the intensity of mRNA signal is additionally induced 
3 days after SNT. Like the other genes, osteopontin is mainly expressed by neurons (Figure 
2). Induction of α7-integrin mRNA after SNT is clearly confirmed by in situ hybridization. 
Very little signal is detected in the non-injured DRG, due to the short exposure time in order 
to show strong mRNA induction, whereas high levels of signal are found 3 days following 
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SNT (Figure 2). In addition we find more than 50 genes whose expression is either up- or 
down-regulated 1.4 fold or more by SNT in the lumbar DRG of adult rats (Table 1). 
 
Dorsal rhizotomy (DR) is not an adequate signal to induce GAP-43 expression whereas it 
regulates the expression of other genes. 
A dorsal rhizotomy (DR) cuts all of the central axons of a single DRG. It is believed 
that injury to the central branch of a sensory ganglion neuron is generally not a strong enough 
signal to induce substantial changes in gene expression. GAP-43 expression is known not to 
be affected by DR (Chong et al., 1994). Expression levels of α-internexin are not changed by 
DR and stay beyond the levels found for SNT at every time-point tested. We find that in 
contrast to the examples of GAP-43 and α-internexin (Figure 1A and B). DR can profoundly 
induce changes in gene expression in the adult lumbar DRG. Glypican-1 has been previously 
described to be up-regulated in the lumbar DRG after spinal cord injury as well as three days 
after DR (Bloechlinger et al., 2004). We show here that glypican-1 mRNA levels peak 7 days 
post-DR (1.4 fold) and remain elevated for at least 21 days after DR (1.4 fold, Figure 1C). α-
fodrin mRNA is not regulated by DR at any time-point investigated (Figure 1D). Osteopontin 
mRNA expression after DR mimics the expression profile seen after SNT, although changes 
are slightly less profound. mRNA levels are strongly up-regulated 3 days post-DR (1.6 fold), 
declining over time towards the non-injured condition (Figure 1E). Similar to osteopontin, 
changes in α7-integrin mRNA after DR resemble the induction after SNT, although changes 
in α7-integrin expression are very modest with a peak in intensity at 3 days post-DR (fold 
changes < 1.4, Figure 1F). Apart from Glypican-1 and Osteopontin, the expression of 50 
genes is found to be regulated by injury to the central processes of DRG neurons by chip 
analysis (Table 1). 
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Slot-blot analysis compares gene expression in two different paradigms in which axons of 
DRG neurons are able to grow: the early postnatal state and peripheral axotomy (SNT). 
Slot-blot analysis confirms the findings of the Affymetrix gene chips and in situ 
hybridization for GAP-43. GAP-43 mRNA is abundant in the naïve DRG, however its 
expression is much higher in states of axonal outgrowth, demonstrated for the case of early 
postnatal developing DRG neurons (postnatal day 0 (P0)) and reactive up-regulation after 
injury to the peripheral branch of DRG neurons at different time-points (3 days and 14 days 
post-SNT; Figure 3A). Furthermore, we confirm higher levels of α-internexin mRNA in P0 
lumbar DRGs than in naïve adult (Figure 3B). As seen by in situ hybridization (Figure 2), no 
obvious induction of α-internexin mRNA is found either 3 days or 14 days following SNT. 
Glypican-1 mRNA expression is very much comparable to that of GAP-43 in terms of high 
expression in neurons whose axons are extending (Figure 3C, 1C and 2). α-fodrin mRNA is 
very abundant in DRGs in every state examined by slot-blotting confirming the results of the 
chip analysis and in situ-hybridization (Figure 3D). At P0, mRNA of osteopontin could not be 
detected, whereas it is strongly expressed in the naïve DRG (Figure 3E). SNT induces 
osteopontin mRNA expression profoundly, showing a short lasting peak in expression 3 days 
post-SNT, followed by mRNA levels that are close to non-injured levels 14 days after injury 
(Figure 3E). α7-integrin mRNA expression is found lower at P0 compared to adult, and 
strongly induced following peripheral axotomy at both time-points examined (Figure 3F). 
 
Gene expression in the motor-cortex is developmentally regulated, but a thoracic spinal 
cord injury does not influence mRNA levels of the genes investigated. 
GAP-43 and glypican-1 share a common expression pattern in the motor cortical area 
of the adult rat brain. Both genes are highly expressed at P0 (Figure 3A and C), a stage in 
CNS development when neuronal differentiation and axonal plasticity is still very high 
(Bennett et al., 1996; Koltzenburg, 1999; Marti et al., 1987). The mRNA of both genes is 
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clearly detected in the adult motor-cortex revealing constitutive gene expression when CNS 
development is finished (Figure 3A and C). Cutting the axons of the major part of neurons 
contributing to the corticospinal tract and weakening ascending cortical input of dorsal 
column fibers via dorsal column nuclei and the thalamus by a dorsal column lesion (DCL) in 
the spinal cord does not visibly affect the expression of GAP-43 nor glypican-1 in the motor-
cortical area (Figure 3A and C). α-internexin, with a similar expression pattern in the DRG 
during development as GAP-43 is, in contrast to GAP-43, constitutively expressed at high 
levels in the motor-cortex of neonatal and naïve adult rats (Figure 3B). There is no change in 
expression following DCL. Maintaining the very stable expression in the DRG during 
development and after injury, α-fodrin mRNA is strongly expressed at similar levels in the 
developing and mature motor-cortex, and its expression is not influenced by a lesion to the 
dorsal funiculus of the spinal cord (Figure 3D). Osteopontin mRNA is not detected in the P0 
and adult motor-cortex (Figure 3E). In contrast to axonal injuries to DRG neurons, DCL does 
not induce mRNA expression in the area of projecting corticospinal neurons whose axons are 
injured (Figure 3E). Very low constitutive levels of α7-integrin mRNA are found in the 
developing and mature motor-cortical areas and levels do not appear influenced by DCL at 
any time-point examined (Figure 3F). In summary, there is differential mRNA expression 
between P0 and adult for two genes examined, GAP-43 and glypican-1, whereas a spinal cord 
injury does not effect the expression of all examined genes in the motor-cortex.  
 
Differentially regulated genes during development and after injury can be grouped 
according to their expression pattern. 
Growth associated protein 43 (GAP-43) is characterized by its strong expression in 
DRG neurons during development and after peripheral nerve injury as well as by the lack of 
induction following injury to the central branch of DRG neurons. Using gene chip analysis we 
find five genes additional to GAP-43, namely neuroglycan C, synaptic vesicle protein (SV2), 
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EF-1-alpha, brain specific peptide and AIF-C1 which share the same features regarding their 
expression (Table 1 (A)). 
We have further identified 7 genes whose mRNA is regulated as outlined for glypican-
1, meaning high expression during development and enhanced levels following injury either 
to the peripheral or the central axons of DRG neurons: VGF, synaptotagmin IV, CCHL2A, 
dual specificity protein tyrosine phosphatase, protein kinase C receptor, neuronatin alpha and 
ADP-ribosylation factor-like protein 3; Table 1 (C)). 
High developmental expression without changes in expression following injury as for 
α-fodrin is the expression pattern of thirty-two additional genes (Table 1 (B)). 
Furthermore, six genes mimic the expression pattern of osteopontin, revealing decreased 
expression levels during development and induced mRNA levels following injury to the 
sciatic nerve as well as the corresponding dorsal root: decorin, RET ligand 1 = GDNF 
receptor alpha, glutamine synthetase glnA, p41-Arc and the immediate-early serum-
responsive JE gene (Table 1 (E)).  
Three genes show the same expression profile (low expression during development, 
induction only after peripheral but not following central axotomy) as α7-integrin: monoamine 
oxidase A, CDP-diacylglycerol synthase and interferon induced mRNA (Table 1 (F)).  
Five genes are found to have expression levels below the ones found in the adult non-
injured DRG during development and after DR; they include stearoyl-CoA desaturase 2 and a 
homologue, EF-hand Ca2+-binding protein p22, calmodulin III and MHC class I RT1.O type 
– 149 processed pseudogene (Table 1 (D)). 
Nine genes show lowered mRNA levels during development and following SNT, but 
remain not influenced by DR (Table 1 (J), seventeen are additionally down-regulated by DR 
(Table 1 (I)). Injury-induced down-regulation with normal or increased mRNA levels during 
development has been found for seven genes (Table1 (H)). We find down-regulated mRNA 
expression during development without influence of injury in seventeen genes (Table 1 (G)). 
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 The remaining 16 genes do not share the expression pattern of any of the groups 
described so far (Table 1 (K), (L), (M), (N) and (O)). Pattern K includes genes which are not 
regulated by SNT but show inverse regulation throughout development and after DR. Group 
L defines genes which are down-regulated by SNT whereas they show normal or increased 
mRNA levels during development. We never find genes that are inversely regulated following 
peripheral versus central injury and we never find mRNA up-regulation after central injury 
without regulation of the same gene during development. 
 
Many genes coding for ribosomal proteins are highly expressed during nervous system 
development but their expression is not affected by peripheral or axonal injury. 
Surprisingly, 42 genes encoding ribosomal components, are expressed at high levels 
during development compared to the adult DRG (Table 2). The mRNA levels of only six of 
them are affected in the adult at exclusively one time-point examined, by either central or 
peripheral axonal injury (Table 2). The mRNA levels of most of these ribosomal genes are 
highest around E15, with a constant decline towards P0 when most of the genes reveal still 
higher mRNA levels than in the adult state. 
 
 
Discussion 
 
In our study we profile more closely, based on data from microarray analysis in the rat 
lumbar DRG, the expression of five genes during development and after injury to the 
peripheral and the central nervous system and compare them to the expression of GAP-43. 
We selected a number of genes that may be important for growth and regeneration to compare 
with GAP-43, a well-known growth-associated gene, in order to test the hypotheses that 
growth-associated genes are regulated in primary sensory neurons after peripheral axotomy in 
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order to mount a growing phenotype seen during the development of the nervous system. The 
chosen genes differ in their cellular function, all of them have been shown to play roles in 
development, differentiation and growth. α-internexin, a 66kD type IV intermediate filament, 
is the earliest expressed type IV neurofilament during development, and as a structural protein 
involved in neuronal development and aging, with implications in axonal regeneration (Ching 
et al., 1999; Chiu et al., 1989; Levavasseur et al., 1999; McGraw et al., 2002). Glypican-1, a 
glycosyl phosphatidyl inositol linked proteoglycan carrying heparan sulphate side chains, is 
found in the nucleus of neurons, but has also been shown to act as a co-receptor at the cell 
membrane for several ligands influencing neuronal growth (Hu, 2001; Liang et al., 1997). α-
fodrin, a submembranous cytoskeletal protein, is involved in cell stability, neurite outgrowth 
and growth cone adhesion as well as thought to be associated with synaptic activity (Bockers 
et al., 2001; Nakano et al., 2001; Shea et al., 1995; Sobue & Kanda, 1989; Ursitti et al., 
2001). Osteopontin, an RGD(Arg-Gly-Asp)-containing glycoprotein, involved in cell 
adhesion and neurite outgrowth has been described in myelinating Schwann cells of the 
sciatic nerve (Hikita et al., 2003; Jander et al., 2002; Selvaraju et al., 2004). The α7-integrin 
subunit of the laminin-1/-2 receptive molecule α7/β1-integrin has been recently shown to be 
involved in the conditioning-lesion effect in DRG neurons in vitro and in α7-integrin deficient 
mice have reduced facial nerve regeneration (Ekstrom et al., 2003; Werner et al., 2000). 
In summary, developmentally up-regulated genes (GAP-43, glypican-1) are induced 
after SNT in the adult, although the changes differ profoundly in strength and dynamics. 
Glypican-1 and α-fodrin, both expressed at relatively constant levels in the embryonic and 
adult DRG, are differentially regulated by SNT. Glypican-1 is up-regulated over a long period 
of time, whereas α-fodrin mRNA shows no significant regulation. The two genes with the 
strongest expression in the adult compared to developmental stages, osteopontin and α7-
integrin, are identically up-regulated in the DRG after SNT, with mRNA levels peaking 3 
days post-injury. DR is a strong inducer of changes in gene expression in the adult lumbar 
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DRG. Whereas GAP-43 and α-fodrin do not show any change in expression following DR, 
the expression of two examined genes does change after DR. Assuming cut off ≥1.4 fold 
change for significant changes in intensity, osteopontin (1.6 fold) is transiently up-regulated 
around day 3 post-DR, mimicking changes seen after SNT. Glypican-1 is the only gene that is 
found to be chronically up-regulated over 21 days (7d 1.4 fold, 21d 1.4 fold). α7-integrin does 
not change following DR. All examined genes are predominantly expressed in DRG-neurons 
of the adult non-injured rat as well as following sciatic nerve transection.  
The study of mRNA expression in the developing and adult motor-cortex reveals that 
only two out of the six examined genes, GAP-43 and glypican-1, are regulated. They both 
appear at high levels shortly after birth (P0) and are expressed at considerably lower levels in 
the adult cortex. Osteopontin is the only gene whose mRNA could not be detected in the 
motor-cortex. A spinal cord injury, cutting the axons running in the dorsal funiculus, 
including axons from the motor-cortex (dCST) and ascending fibers of the dorsal column 
system, is not a strong enough signal to evoke changes in the mRNA expression of the 
examined genes. This may be because the axonal injury site of CST fibers is at greater 
distance from the cell body and neural networks in the cortex may stabilize gene expression 
more successfully than in the periphery. Another explanation for the stable gene expression in 
the motor-cortical area following DCL may be that the pyramidal cells whose axons constitute 
the CST make up only a very minor proportion of all the cells in the motor-cortex. Therefore 
changes only in those injured pyramidal cells may not be detected with the technique we used.   
Examining gene expression in the lumbar DRG during development and following 
injury to the peripheral or central branches of DRG axons show strong regulation of mRNA 
levels for more then 120 genes, whose expression patterns can be grouped comparing 
regulation during development and after injury, without taking further into account the 
dynamics of changes.  We find for each closely examined gene, except for α-internexin that 
was attributed an absent (A) call in the naïve adult DRG, between 3 and 32 genes which show 
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the same expression pattern. In addition we define other expression patterns as shown in table 
1, but interestingly, even though we find very different expression patterns, mRNA levels for 
a given gene have never been found to be inversely regulated following central and peripheral 
injury respectively. These data suggest that there is a common process underlying the 
transcriptional response to injury of the central and peripheral branches of DRG neurons, 
which can be tuned by the presence or lack of environmental factors acting on the injured 
axon at the site of injury or along the axon, or by the lack of target-derived signals. These 
mechanisms could therefore account for the differential gene expression seen in our injury 
paradigms and during development.  
Many genes encoding for ribosomal proteins appear to be expressed at high levels 
during the embryonic period. It is quite remarkable the transcription of almost none of these 
genes is affected by either central or peripheral injury, an influence where one could assume 
that the translational machinery of a cell would have to be strengthened. We cannot exclude 
however that these changes occur on a translational level. For the genes not examined by in 
situ-hybridization it remains unclear whether non-neuronal cells in the DRG may account for 
some of the changes detected by microarray analysis. 
From our study, it is clear that injury to the peripheral and central branch of DRG 
axons does not cause the recapitulation of a developmental transcriptional program for every 
gene that may be involved in growth- and regeneration-related functions in the nervous 
system. Therefore we suggest a more detailed classification of expression-profiles than that of 
growing versus not-growing phenotypes of DRG-neurons. According to our findings, we 
propose a further subdivision into a “developmental-growing phenotype” and an “injury-
induced growing phenotype”. GAP-43, for example would fit both criteria, therefore defining 
the “growing phenotype”. On the other hand, osteopontin does not seem to be needed for 
developmental growth, although it may play roles in the “injury-induced growing phenotype”.  
Taking into account the findings of osteopontin and glypican-1 expression, it makes sense to 
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add a third category of gene expression patterns, the “central-injury-induced phenotype”. 
Osteopontin therefore can be clearly characterized as an injury-related (peripheral and central) 
gene in the adult nervous system, α7-integrin as part of the “injury-induced growing 
phenotype” with possible functions in development. Glypican-1 shows the most complex 
differential expression, with components of the overall “growing phenotype” as well as 
overall “injury-related”. We clearly identify GAP-43 as a characteristic gene representing a 
“growing phenotype”. It is important to understand the growth and injury-regulated 
expression of genes in the nervous system in order to better understand the conditions 
required for re-growth and functional recovery after injury. 
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Axonal injury-dependent induction of the peripheral
benzodiazepine receptor in small-diameter adult
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Abstract
The peripheral benzodiazepine receptor (PBR), a benzodiazepine but not c-aminobutyric acid-binding mitochondrial membrane
protein, has roles in steroid production, energy metabolism, cell survival and growth. PBR expression in the nervous system has been
reported in non-neuronal glial and immune cells. We now show expression of both PBR mRNA and protein, and the appearance of
binding of a synthetic ligand, [3H]PK11195, in dorsal root ganglion (DRG) neurons following injury to the sciatic nerve. In naı¨ve
animals, PBR mRNA, protein expression and ligand binding are undetectable in the DRG. Three days after sciatic nerve transection,
however, PBR mRNA begins to be expressed in injured neurons, and 4 weeks after the injury, expression and ligand binding are
present in 35% of L4 DRG neurons. PBR ligand binding also appears after injury in the superficial dorsal horn of the spinal cord. The
PBR expression in the DRG is restricted to small and medium-sized neurons and returns to naı¨ve levels if the injured peripheral
axons are allowed to regrow and reinnervate targets. No non-neuronal PBR expression is detected, unlike its putative endogenous
ligand the diazepam binding inhibitor (DBI), which is expressed only in non-neuronal cells, including the satellite cells that surround
DRG neurons. DBI expression does not change with sciatic nerve transection. PBR acting on small-calibre neurons could play a role
in the adaptive survival and growth responses of these cells to injury of their axons.
Introduction
Primary sensory neurons, with cell bodies in the dorsal root ganglion
(DRG) convey information along their axons from the periphery to the
central nervous system. The diameter of the sensory neuron cell bodies
and their axons, as well as their degree of myelination, corresponds to
the modality of the information they convey. In general, large and
medium diameter myelinated neurons carry proprioceptive and
cutaneous mechanoreceptive information, respectively, whereas smal-
ler myelinated and unmyelinated neurons transmit thermoreceptive
and nociceptive information (Lawson, 2002).
When an adult peripheral nerve is injured, the injured sensory
neurons show altered levels of mRNA and proteins for numerous
molecules, in the switch from a differentiated transducing and
neurotransmitting state, to one in which the need for survival and
regrowth becomes predominant (Lieberman, 1971; Aldskogius et al.,
1985). Microarray analysis has recently revealed the extent and com-
plexity of the injury-induced changes in gene-expression identifying
hundreds of up- and downregulated genes in the DRG after axotomy
(Costigan et al., 2002; Xiao et al., 2002).
Among those genes of which the expression increases in the DRG
after axonal injury, is the peripheral benzodiazepine receptor
(PBR; Costigan et al., 2002; Xiao et al., 2002). Like the central
c-aminobutyric acid (GABA)A receptor, PBR binds benzodiazepines,
but unlike the GABAA receptor it does not bind GABA and has a
distribution and action quite distinct from the central benzodiazepine
receptor, which is a chloride ion channel inserted in the plasma
membrane (DeLorey & Olsen, 1992). First identiﬁed in peripheral,
non-nervous tissues (Braestrup & Squires, 1977), PBR is a
mitochondrial membrane protein with widespread expression through-
out the body, particularly in steroidogenic tissues (Amsterdam & Suh,
1991; Papadopoulos, 1993) and in leukocytes (Cahard et al., 1994). In
the nervous system, PBR has been identiﬁed in the choroid plexus, the
ependymal linings, astrocytes and microglia (Benavides et al., 1983;
Moynagh et al., 1991; Itzhak et al., 1993; Park et al., 1996).
The diazepam binding inhibitor (DBI), a 10 kDa polypeptide found
within brain and other regions of the body, along with porphyrins, have
been proposed to be endogenous ligands for the peripheral benzodia-
zepine receptor (Guidotti et al., 1983; Snyder et al., 1987; Verma et al.,
1987). Several pharmacological ligands also bind to the receptor and
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elicit a wide range of effects (Braestrup & Squires, 1978; Le Fur et al.,
1983; Trapani et al., 1999; Ferzaz et al., 2002). PBR-activating ligands
stimulate steroidogenesis (Besman et al., 1989; McCauley et al., 1995;
Lacor et al., 1999), have anti-inﬂammatory and antinociceptive effects
(Bressan et al., 2003; Torres et al., 2000; Lazzarini et al., 2001; DalBo
et al., 2004; Farges et al., 2004), promote the survival and repair of
injured motor neurons (Ferzaz et al., 2002) and protect against
apoptosis (Bono et al., 1999; Strohmeier et al., 2002). Increases in PBR
levels and binding occurs in the nervous system in microglia in a
number of neuropathological conditions including Alzheimer’s disease
(Diorio et al., 1991), Huntington’s disease (Messmer & Reynolds,
1998), multiple sclerosis (Vowinckel et al., 1997) and amyotrophic
lateral sclerosis (Sitte et al., 2001) and, because of this, PBR has been
used clinically as a microglial marker (Miettinen et al., 1995; Leong
et al., 1996). PBR expression also increases in glia following nerve
injury (Gehlert et al., 1997; Lacor et al., 1996), neurotoxic lesions
(Kuhlmann & Guilarte, 2000) and ischemia (Stephenson et al., 1995).
In this study, we now examine the extent, timing and cellular
localization of the increased PBR expression and ligand binding in
DRG following sciatic nerve transection and crush injury, along with
the expression of its putative endogenous ligand, DBI.
Materials and methods
Animal surgery and tissue preparation
All procedures were performed in accordance with Massachusetts
General Hospital Animal Research regulations. To produce sciatic
nerve transection and crush injuries, adult male Sprague–Dawley rats
(200–300 g; Charles River Laboratories, MA, USA) were anaesthet-
ized with isoﬂurane (inhalation induction, 4%; maintenance, 2.5%),
the left sciatic nerve was exposed at the mid-thigh level, ligated with
3 ⁄ 0 silk and sectioned immediately distal to the ligation (sciatic nerve
transection lesion; SNT), or exposed and crushed with a ﬁne, smooth-
bladed haemostat forceps for 30 s (crush injury). Two other partial
peripheral nerve injuries known to produce neuropathic pain-like
hypersensitivity were also performed. The spared nerve injury model
(SNI) involves ligation and section of two of the three terminal
branches of the sciatic nerve, the tibial and common peroneal nerves,
leaving the sural nerve intact, and was performed as previously
described (Decosterd & Woolf, 2000). For the chronic constriction
injury model (CCI), four 4–0 chromic gut sutures spaced 1 mm apart
were tied loosely around the sciatic nerve proximal to its trifurcation
(Bennett & Xie, 1988). The wound was sutured in two layers and the
animals were allowed to recover for 1–28 days.
For collection of fresh tissue, animals were terminally anaesthetized
by exposure to CO2 and exsanguinated. The L4 and L5 DRGs and
lumbar spinal cord were rapidly removed, embedded in OCT
compound (Tissue Tek, Fisher, PA, USA), frozen, and stored at
)80 C. Additional DRGs were taken from rat pups at postnatal days
0, 7 and 10 (P0, P7 and P10) after the animals had been decapitated.
For ﬁxed tissue, rats were anaesthetized, perfused transcardially with
phosphate-buffered saline (PBS) followed by Zamboni’s ﬁxative.
Dissected tissue was postﬁxed for 60 min, cryoprotected in 10%
sucrose in 0.1 m phosphate buffer overnight at 4 C before being fast
frozen in cryomolds. Before cryostat sectioning, frozen blocks
containing spinal cords or pairs of DRGs from animals injured at
different time points and from naı¨ve animals were blocked together
with OCT compound to ensure processing of different experimental
groups under identical conditions on the same slide. Serial sections of
fresh and ﬁxed frozen tissue were cut at 6 lm, thaw-mounted onto
cold Probe-On slides (Fisher) and stored at )20 C.
Isotopic in situ hybridization
In situ hybridization was carried out as described previously
(Karchewski et al., 1999) using 48-base pair oligonucleotide probes
complementary to, and selective for, the following mRNAs: peripheral
benzodiazepine receptor (PBR; Accession #J05122); neuroﬁlament
heavy chain (NFH; Accession #AF031879); and DBI (Accession
#NM031853). Each oligonucleotide probe (80 ng) was labelled at the
3¢ end with a-[35S]dATP or a-[33P]dATP (NEN, MA, USA) in a
terminal transferase reaction and puriﬁed through a spin column
(Qiagen, CA, USA). Speciﬁc activities ranged from 2.0–5.2 ·
106 c.p.m. ⁄ ng oligonucleotide.
Slides were hybridized at 43 C for 14–18 h in a buffer containing
50% formamide, 4 · saline sodium citrate (SSC), 1 · Denhardt’s
solution (0.02% bovine serum albumin, 0.02% Ficoll and 0.02%
polyvinylpyrollindone), 1% sarcosyl (N-laurylsarcosine), 0.02 m
phosphate buffer (pH 7.0), 10% dextran sulphate, 500 mg ⁄mL heat-
denatured salmon sperm, 200 mm dithiothreitol and 107 c.p.m. ⁄mL of
radiolabelled oligonucleotide probe. The slides were then washed four
times for 15 min in 1 · SSC at 55 C, brought to room temperature,
dipped twice in distilled water, dehydrated in ascending alcohols and
air-dried. The hybridization stringency conditions used required
homologies > 90% for retention of the transcripts following the
washes (Dagerlind et al., 1992). Slides were stored at 4 C until
processed by emulsion autoradiography.
The speciﬁcity of the hybridization signal for each probe was
ascertained by hybridization of adjacent sections with labelled probe,
labelled probe with a 1000-fold excess of cold probe, or labelled probe
with a 1000-fold excess of another, dissimilar cold probe of the same
length and similar G–C content.
In situ [3H]PK11195 binding
In situ PBR ligand binding was performed by incubating slides of
unﬁxed tissue for 2 h at 4 C in 50 mm saline Tris-HCl (pH 7.4)
containing 2 nm [3H]PK11195 ([1-(2-chlorophenyl)-N-methyl-N-
(1-methylprolyl)-3-isoquinoline carboxamide]; speciﬁc activity
85 Ci ⁄mmol, NEN). To assess nonspeciﬁc binding, control slides
were incubated in a similar solution containing unlabelled 10 lm
PK11195 (Sigma, MO, USA). Following incubation, the slides were
washed in cold buffer and air-dried before being processed by
emulsion autoradiography.
Emulsion autoradiography
Under safelight conditions, slides were dipped in NTB-2 nuclear
track emulsion (Kodak; 1 : 1 in distilled water) dried and stored in
light-proof slide boxes with desiccant at 4 C. The sections were
exposed for 1–12 weeks (time determined by test slides) before
being developed and ﬁxed. For viewing under darkﬁeld conditions
using a ﬁbre-optic darkﬁeld stage adapter (MVI, MA, USA), slides
were left unstained and coverslipped using glycerol. For viewing
under the brightﬁeld microscope, slides were counterstained with
0.5% Toluidine blue (pH 4–4.5), differentiated and coverslipped
using Permount (Fisher). Photographs were taken using a Spot
camera (MVI).
Quantification and analysis
Using single section proﬁle counts, 4–6 sections chosen randomly
from each L4 and L5 DRG were counted in 3–4 animals from naı¨ve,
672 L. A. Karchewski et al.
ª 2004 Federation of European Neuroscience Societies, European Journal of Neuroscience, 20, 671–683
109
3 days, 1 week and 3 and 4 weeks post-SNT, and the proportion of
labelled neuronal proﬁles for each time point calculated. To reduce
bias and to prevent the counting of cell edges, a neuron was only
counted if its nucleus was visible. Cells were considered positively
labelled if they had more than ﬁve times background level of
autoradiographic label (silver grains) when observed under brightﬁeld
conditions with a 20 · objective.
For mRNA and binding size frequency distributions of neuronal
proﬁles, brightﬁeld microscope images were captured using a Spot
camera from ﬁve sections per L4 DRG from four animals at each
time point (naı¨ve and 4 weeks) following SNT. Using photomon-
tages of each DRG, cell diameters were measured across the widest
portion of every positively and negatively labelled cell containing a
nucleus. Values reﬂect measurements adjusted according to scale.
Diameters < 30 lm, 30–45 lm and > 45 lm represent small,
medium and large neurons. Prism 4 software (Graphpad, San
Diego, CA, USA) was used for statistical analysis and graphing.
One-way anova followed by Dunnett’s multiple comparison tests
were used to test for signiﬁcant differences. All data are presented
as mean ± SEM.
Immunohistology
Slides for PBR and NF200 immunohistology (cut from fresh tissue)
were ﬁxed in cold 70% ethanol for 10 min at 20 C. Tissue
sections were washed in PBS (0.1 m) and blocked for 1 h at room
temperature in a PBS solution containing 5% bovine serum albumin
and 0.1% Triton X-100. Slides for DBI and glial ﬁbrillary acidic
protein (GFAP) immunohistology (cut from ﬁxed tissue) were
washed in PBS (0.1 m) and treated with a blocking solution
containing 10% horse serum and 0.1% Triton X-100 in PBS for 1 h
at 4 C. All slides were incubated overnight at 4 C with their
primary antibodies diluted in blocking solution: rabbit anti-PBR
(1:200; R & D Systems, MN, USA); mouse anti-neuroﬁlament 200
(NF200, 1:800; Sigma); rabbit anti-DBI fragment (1:300; Peninsula
Laboratories Inc, CA, USA); and mouse anti-GFAP (1:200, ﬁnal
concentration 5 lg ⁄mL; Chemicon, CA, USA). PBS washes were
followed by incubation with Cy3-conjugated goat anti-rabbit IgG
(1:400; Jackson ImmunoResearch, ME, USA) and FITC-conjugated
donkey anti-mouse IgG (1:200; Jackson ImmunoResearch) in
blocking solution without Triton X-100 for 1 h at room temperature
Fig. 1. PBR mRNA is induced in small and medium-sized primary sensory neurons after SNT. (A) Representative photomicrographs of L4 DRG sections
processed for PBR mRNA by in situ hybridization from naı¨ve animals and 3 days, 1 week and 3 weeks after sciatic nerve transection. Scale bar, 200 lm.
(B) Photomicrographs showing adjacent 6 lm DRG sections processed by in situ hybridization for PBR mRNA and neuroﬁlament heavy chain (NFH; a marker of
large-diameter neurons) mRNA expression 3 weeks post-SNT. Stars show examples of large-sized neurons, indicated by a positive NFH signal, that have no
detectable signal for PBR mRNA. Arrows show small and medium-sized neurons, not labelled for NFH, with positive hybridization signal for PBR. Arrowheads
point to unlabelled, non-neuronal cells. Scale bar, 50 lm.
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in the dark. Slides were washed in PBS and coverslipped with
Vectashield (Vector Laboratories Inc., CA, USA). Sections were
viewed with a ﬂuorescent microscope (Nikon) and photographed
using a Spot digital camera. Immunohistology controls showed no
signal when primary antibody was replaced with blocking solution.
Results
Peripheral axotomy induces PBR mRNA expression in small
and medium-sized primary sensory neurons
In a previous Affymetrix microarray screen of changes in gene
expression in the DRG after peripheral nerve injury, we found 240
genes that were signiﬁcantly up- or downregulated in the L4
and L5 DRG 3 days after a sciatic nerve transection (Costigan
et al., 2002). The peripheral benzodiazepine receptor (Accession
#J05122) was increased 1.56-fold relative to naı¨ve (P ¼ 0.0139) at
this time.
Isotopic in situ hybridization detecting PBR mRNA correspond-
ing to the isoquinoline binding protein (IBP) component of the
receptor was used to examine adult rat DRGs at different times
following SNT. No constitutive PBR mRNA is detectable in the
naı¨ve, noninjured DRG (Figs 1A and 4A). Three days following a
SNT, PBR mRNA expression is detected in a subset of sensory
neurons in the DRG ipsilateral to the injury (20.36 ± 0.98%) and
this becomes even more pronounced 1 and 3 weeks post-SNT
(30.93 ± 2.03% and 32.59 ± 1.11%; Figs 1A and 4A). At the longest
time examined after the injury, 4 weeks, the PBR hybridization
signal remained highly elevated compared with naı¨ve and contra-
lateral DRGs (4 weeks: 33.47 ± 0.92%). No detectable hybridization
signal for PBR mRNA is observed in non-neuronal cells in DRGs
from either naı¨ve or nerve-injured animals (Fig. 1B). Size frequency
histograms of DRG neuron cell diameters and of PBR mRNA-
positive neurons, reveal that PBR mRNA expression is restricted to
small and medium diameter neurons when measured at 4 weeks
post-injury (Fig. 4D). Out of 269 neuronal proﬁles labelled for PBR
mRNA at 4 weeks post-injury, 108 (40.15%) had diameters between
30 lm and 45 lm, 158 (58.74%) were less than 30 lm and none
were larger than 45 lm (Fig. 4D). PBR mRNA is virtually
undetectable in cells with large diameters at any time point after
injury (Fig. 4D) and no coexpression is found with NFH mRNA, a
marker of neurons with myelinated axons (Fig. 1B; Michael &
Priestley, 1999).
Axotomy induces PBR protein expression in small and medium
primary sensory neurons
Peripheral nerve transection produces changes in PBR protein
expression similar to that of its mRNA. Immunostaining does not
show any detectable PBR protein in naı¨ve DRGs or those contralateral
Fig. 2. PBR protein expression is induced in small and medium-sized primary sensory neurons after SNT. (A) Photomicrographs show PBR immunoreactivity in
DRG from naı¨ve animals and 3 weeks after SNT. Scale bar, 100 lm. (B) Double-labelling of PBR (red) with NF200 (green) to show large-sized neurons or with
GFAP (green) to show non-neuronal cells in the DRG 3 weeks after SNT. PBR expression is limited to the small- to medium-sized neurons of the injured DRG.
Scale bar, 50 lm.
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to the injury (Fig. 2A). Levels of PBR immunostaining are present
3 weeks post-SNT. No overlap when double-labelled with NF200
(marker of A-ﬁbre neurons) and GFAP (marker of non-neuronal cells
in the DRG) antibodies indicates that PBR immunoreactivity, similar
to its mRNA expression, appears only in small and medium-sized
neurons after SNT (Fig. 2B).
Fig. 3. [3H]PK11195 binding appears in primary sensory neurons after SNT. (A) Representative darkﬁeld photomicrographs of L4 DRG sections processed to
detect PBR binding sites by in situ receptor binding using the high-afﬁnity PBR ligand [3H]PK11195 in naı¨ve and 3 days, 1 week and 3 weeks after SNT. Speciﬁc
PBR binding appears 1 week after SNT and shows an increase to 3 weeks. All speciﬁc binding is successfully competed using an excess of unlabelled speciﬁc ligand
(cold). Scale bar, 200 lm. (B) No PBR mRNA or [3H]PK11195 binding is detectable in the naı¨ve, early postnatal DRG (P0). Scale bar, 10 lm.
(C) Photomicrographs showing [3H]PK11195 binding in a DRG 3 week post-SNT with an adjacent 6-lm-thick DRG section processed by in situ hybridization to
detect mRNA for PBR. Arrows show examples of neurons in adjacent sections with positive signal of both [3H]PK11195 binding and PBR mRNA, whereas stars
show examples of neurons without positive levels of either binding or PBR mRNA. Scale bar, 50 lm.
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PBR ligand binds to small and medium primary neurons
in the DRG following sciatic nerve transection
To determine if the increases in PBR mRNA and protein after nerve
injury are accompanied by changes in functional binding properties of
DRG neurons to a ligand for the peripheral benzodiazepine receptor,
we examined PBR binding using [3H]PK11195, a high afﬁnity PBR
ligand (Le Fur et al., 1983). PBR mRNA and [3H]PK11195 binding is
not detectable in naı¨ve DRG neurons when they are still in the
Fig. 4. Quantiﬁcation of injured primary sensory neurons showing parallel changes in [3H]PK11195 binding and PBR mRNA expression. (A) The percentage of
L4 DRG neurons positively labelled for PBR mRNA after SNT (n ¼ 5–8 DRG at each time point, 4–5 sections per DRG). F4,33 ¼ 136.7, P < 0.0001 (one-way
anova); **P < 0.01 (Dunnett’s multiple comparison test). (B) The percentage of DRG neurons positive for [3H]PK11195 binding after SNT (n ¼ 5–7 DRG at
each time point, 4–5 sections per DRG). F4,25 ¼ 356.4, P < 0.0001 (one-way anova); **P < 0.01 (Dunnett’s multiple comparison test). (C) Histogram showing the
relative size distribution of L4 DRG neurons in naı¨ve and 4 weeks following SNT. (D and E) Histograms showing the number and size distribution of PBR mRNA
(D) and [3H]PK11195 binding (E) positive cells in comparison with the whole DRG cell population 4 weeks following SNT.
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postnatal growing phase at P0 (Fig. 3B) or at P7 or P10 (data not
shown), suggesting that PBR is not required in the DRG under
normal circumstances or during periods of developmental growth.
Virtually no [3H]PK11195 binding occurs in naı¨ve adult DRG
sections and receptor binding is also not detectable 3 days post-injury
(Figs 3A and 4B). At both 1 and 3 weeks after SNT, clear
[3H]PK11195 binding is present in 26.76 ± 1.40% and
31.62 ± 0.96% of all DRG neuronal proﬁles. At 4 weeks post-injury,
the latest time point examined, 35.45 ± 0.87% of DRG neuron
proﬁles were positive (Fig. 4B). The [3H]PK11195 binding colocal-
izes with PBR mRNA in DRG neurons after injury (Fig. 3C).
Changes in the proportion of neuronal proﬁles positive for
[3H]PK11195 binding 1 week and 3 weeks after SNT follows the
timecourse of PBR mRNA induction following SNT (Fig. 1), with a
slight delay (Fig. 4B).
Size–frequency histograms of cell diameters in the DRG show that
[3H]PK11195 binding is only found in small and medium diameter
neurons 4 weeks post-injury (Fig. 4E). Out of 233 neuronal proﬁles,
97 (41.63%) had diameters between 30 lm and 45 lm and 136
(58.37%) had diameters < 30 lm (Fig. 4E). Speciﬁcity of ligand
binding is conﬁrmed by the competition of [3H]PK11195 with excess
concentrations of unlabelled cold PK11195 (Fig. 3A).
Binding of [3H]PK11195 increases in lumbar spinal cord
following a sciatic nerve transection
No [3H]PK11195 binding is detectable in naı¨ve spinal cord, but is
found following SNT (Fig. 5). Three days after SNT, binding appears
in the spinal cord (data not shown) and 3 weeks post-SNT a strong
PBR binding signal is found in the dorsal horn. [3H]PK11195
autoradiographic signal is most abundant in laminae I and II of the
dorsal horn.
PBR mRNA and [3H]PK11195 binding in the DRG show
target-dependent expression in the adult
Similar to SNT, a sciatic nerve crush injury causes induction of
PBR mRNA and binding with a slow onset and high levels of
expression 2 weeks post-injury in the adult (Fig. 6). In contrast to
SNT with ligation, crushed ﬁbres are provided with an endoneurial
tract along which to grow and are capable of successful regener-
ation. Four weeks after the nerve crush the levels of PBR mRNA
and [3H]PK11195 binding are reversed close to the levels before
injury, unlike after a transected sciatic nerve where PBR expression
and binding remain elevated (Fig. 6). At this time most crush-
injured ﬁbers will have regrown to innervate peripheral targets
(Devor et al., 1979).
The endogenous ligand for PBR, DBI, is present
in the injured and noninjured DRG
Coexpression of PBR with its putative endogenous ligand, DBI, was
explored by in situ hybidization. DBI mRNA is expressed in DRG but
exclusively in non-neuronal cells, as indicated by hybridization signal
appearing only in rings surrounding DRG neurons and no colocali-
Fig. 5. Sciatic nerve transection induces [3H]PK11195 binding in the lumbar spinal cord. Darkﬁeld photomicrographs showing 6-lm-thick sections of adult rat
lumbar spinal cord processed for in situ receptor binding using the high afﬁnity PBR ligand [3H]PK11195 to detect PBR binding sites in naı¨ve animals and 3 weeks
following SNT. Speciﬁc binding appears in laminae I and II of the dorsal horn (bottom panels). All speciﬁc binding is successfully competed using an excess of
unlabelled speciﬁc ligand (cold). Scale bars, 300 lm (top panels); 130 lm (lower panels).
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zation with PBR mRNA (Fig. 7A and B). Similarly, abundant
DBI protein is not localized in DRG neurons but only appears non-
neuronally and partly colocalizes with GFAP, a marker of
non-neuronal cells in the DRG (Fig. 7C). No obvious changes in
DBI levels or expression pattern are detected at any time point
following transection of the sciatic nerve (Fig. 7A).
PBR mRNA and binding are upregulated in small and medium
DRG neurons after partial injuries to the sciatic nerve
Examination of PBR expression 3 weeks after different injuries to the
sciatic nerve shows induction of PBRmRNAexpression and an increase
in [3H]PK11195 binding (Fig. 8A). Each injurymodel produces a partial
transection of the sciatic nerve. In the SNI, two of three distal
Fig. 7. Diazepam binding inhibitor (DBI) is present in non-neuronal cells of the DRG. (A) Darkﬁeld photomicrographs showing 6-lm-thick adjacent DRG
sections from naı¨ve and 4 weeks post-SNT processed for in situ hybridization to detect mRNA for DBI and PBR. No changes in DBI levels are detectable. Scale bar,
200 lm. (B) Arrowheads show examples of injured DRG neurons positive for PBR mRNA and not DBI, while arrows point to non-neuronal cells surrounding
neurons that show strong levels of DBI signal but remain PBR-negative. Scale bar, 50 lm. (C) Photomicrographs show DBI and GFAP immunoreactivity in the
DRG 4 weeks after injury. Scale bar, 40 lm. Right, double-labelling shows that DBI (red) is found perineuronally and colocalizes with GFAP (green). Scale bar,
20 lm.
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contributing branches of the sciatic are cut whereas in the CCI, only a
proportion of the ﬁbres are damaged through a combination of
inﬂammation and strangulation of the sciatic nerve. For each partial
injury, as with complete SNT, PBR mRNA and binding remains
restricted to the small and medium-sized neurons of the DRG (Fig. 8B).
Discussion
Until recent studies by ourselves and others using microarrays
reported upregulation of PBR mRNA in the DRG after nerve injury
(Costigan et al., 2002; Xiao et al., 2002), expression of PBR in the
peripheral nervous system (PNS) had been described only in non-
neuronal cells (Lacor et al., 1996; Lacor et al., 1999). Here we show
that PBR mRNA expression appears in the DRG in sensory neurons
after sciatic nerve transection, with a concomitant increase in PBR
protein from essentially undetectable levels in naı¨ve, noninjured
animals to presence in a substantial proportion of small-caliber
sensory neurons post-injury. To further investigate whether PBR
detected by immunohistology is present in a conformation that can
bind ligand, we have performed in situ receptor binding using the
Fig. 8. Sciatic nerve injuries related to neuropathic pain induce PBR mRNA expression and ligand binding in the DRG. (A) Darkﬁeld photomicrographs show
DRG sections (L4 ⁄ L5) processed for in situ hybridization to detect mRNA for PBR with adjacent sections showing in situ receptor binding for [3H]PK11195. Three
weeks after SNI and CCI, PBR mRNA and binding are signiﬁcantly increased in the DRG. Scale bar, 200 lm. (B) Photomicrographs showing an example of DRG
neurons 3 weeks after SNI processed for in situ hybridization to detect PBR mRNA. Expression of PBR mRNA appears only in small and medium-sized neurons.
Scale bar, 60 lm.
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high-afﬁnity PBR ligand [3H]PK11195. We detect strong binding
1 week following axotomy, in contrast to PBR mRNA which appears
after 3 days, a delay likely to reﬂect the translational and post-
translational dynamics of PBR in DRG neurons. Furthermore, PBR
ligand binding appears in the superﬁcial dorsal horn of the spinal cord
following axotomy in those laminae where small-caliber afferents
terminate. The induced PBR expression in the DRG returns towards
preinjury levels if reinnervation is allowed to occur after a peripheral
nerve crush injury, but not if axonal growth is prevented by a nerve
ligation. No non-neuronal expression of PBR is detectable in the DRG
at any time point following peripheral nerve injury and PBR
expression does not overlap with that of its putative endogenous
ligand DBI, which has an exclusively non-neuronal expression pattern
that does not change following injury. These ﬁndings indicate the need
for a major re-evaluation of the role of PBR in the PNS in general and
particularly in injured small DRG neurons.
PBR is a mitochondrial membrane protein that is involved in the
mitochondrial respiratory chain (Szabo et al., 1993) as well as having
a structural contribution to the mitochondrial permeability transition
pore (MPTP; McEnery et al., 1992; McEnery et al., 1993). PBR
activation initiates steroid biosynthesis (Besman et al., 1989; Papad-
opoulos & Brown, 1995) by facilitating transport of cholesterol from
the outer to the inner mitochondrial membrane making cholesterol
available to cytochrome p450 for the biosynthesis of pregnenolone,
the rate-limiting step in steroid production (Krueger & Papadopoulos,
1990; Krueger, 1995). Cholesterol is a major membrane lipid and is
required both for axonal elongation (de Chaves et al., 1997) and
myelin formation (Magnaghi et al., 2001; Hasse et al., 2002).
Neurosteroid hormones have protective effects and support repair
(Jones, 1993; Schumacher et al., 2000) by both providing metabolic
energy to cells and inhibiting inﬂammatory mediators, and in Schwann
cells they activate the myelin genes, P0 and PMP22 (Koenig et al.,
1995; Ghoumari et al., 2003; Farges et al., 2004). Repair and recovery
of lesioned peripheral nerves has been correlated to PBR activation by
agonists and subsequent increases in local pregnenolone levels (Ferzaz
et al., 2002; Lacor et al., 1999).
In the adult rat, injured DRG neurons survive for many weeks in the
absence of trophic support from their targets (Lewis et al., 1999). This
appears to be the result of induction of intrinsic anti-apoptotic survival
molecules such as the small heat shock protein Hsp27 (Benn et al.,
2002). PBR might be an intrinsic injury-induced neuronal survival
molecule and PBR ligands could have a role in preventing sensory
neuron loss in peripheral neuropathies. PBR ligands might also have
an indirect beneﬁcial effect on injured neurons through their actions on
glia and immune cells (Zavala et al., 1990; Waterﬁeld et al., 1999;
Torres et al., 2000). PBR ligand binding modulates the mitochondrial
transmembrane potential (Chelli et al., 2001; Tanimoto et al., 1999)
and protects cells from damage by reactive oxygen species (Carayon
et al., 1996). These two actions help prevent apoptotic death by
inhibiting cytochrome-c release from mitochondria and subsequent
caspase activation (Bono et al., 1999; Stoebner et al., 2001; Ferzaz
et al., 2002; Strohmeier et al., 2002). The induction of PBR could
have a role therefore in preventing small DRG neurons from dying
after injury to their peripheral axons.
The exclusive neuronal localization of PBR expression and binding
in the DRG after nerve injury suggests a speciﬁc role for this
mitochondrial protein in injured small but not large sensory neurons.
Recently PBR ligands have been shown to cause a steroid-dependent
antinociception (Bressan et al., 2003; DalBo et al., 2004). This,
together with our ﬁndings, suggests that PBR could be a target for
pharmacological intervention in neuropathic pain. DBI is expressed in
satellite cells in the DRG and, if released by these cells, might
represent a source of endogenous ligand for PBR induced in the
injured small DRG neurons, a paracrine glial-neuronal signalling in
the DRG. What action DBI has in noninjured DRG where no PBR is
expressed is not clear. Nevertheless the discovery that PBR is induced
in small-calibre DRG neurons, together with the different functions
that PBR mediates on mitochondria, suggest that this protein takes part
in the important adaptive survival and growth responses of these cells
after injury of their peripheral axons.
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At least three dichotomies are evident in the reaction of the nervous system of higher 
vertebrates to lesions. First, large injuries to the adult nervous system in adult mammals, 
including humans, cause many severe deficits with only a minor tendency to adaptive 
recovery, as is the case for spinal cord injury or stroke. However, the developing CNS shows 
strong adaptive plasticity in terms of behavioral compensation and structural rearrangements. 
The reaction to injuries evokes major compensation in the developing CNS and only minor 
adaptations in the adult. Second, there is a fundamental difference between the regenerative 
capacity of the adult CNS versus the adult PNS. Whereas injured axons of the PNS can re-
grow along perineural sheets of connective tissue and re-innervate peripheral target structures, 
injured axons in the CNS usually retract and do not re-grow. Third, injury to the peripherally 
or centrally projecting axonal branch of DRG neurons, or more generally written, axotomy of 
neurons in different areas of the nervous system elicit cell body responses that vary greatly 
and that have been classified simply by the regulation of some growth- and regeneration-
associated genes, e.g. c-Jun and GAP-43.  Therefore, the dividing neuronal cell body 
responses are separated into two categories, one that allows for axonal regeneration and one 
that does not (for reviews see (Schwab and Bartholdi, 1996; Raineteau and Schwab, 2001; 
Fouad and Pearson, 2004). 
 
The experiments presented in this thesis address the regulation of axonal growth after injury 
in the adult nervous system. Localized injury to the corticospinal tract of a rat only leads to 
minor morphological rearrangements of the injured neuronal system in the adult, most 
importantly axonal regeneration is extremely restricted. By blocking the action of Nogo-A, a 
major myelin-associated inhibitor of axonal growth, some of the environmental influences 
that prevent axonal growth can be abolished (Schnell and Schwab, 1990). We show here that 
the application of monoclonal antibody IN-1 leads to major structural rearrangement after 
unilateral transection of the corticospinal tract at the level of the medulla oblongata. The 
structural plasticity that we observe includes robust sprouting of corticopontine neurites. First, 
we show an increased innervation density of the basilar pons ipsilateral to the injury. Second, 
we find that sprouting axons cross the pontine midline, an axonal growth process that results 
in a new pontine innervation field contralateral to the injured corticospinal tract. Our detailed 
analysis reveals that the newly grown axons that project across the midline terminate in a 
topographical way that strongly resembles the unilateral somatotopic pontine innervation 
found in uninjured animals. A major finding is that these contralaterally projecting axons can 
establish physical connections with the newly innervated target cells. We show, by electron 
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microscopy, synapses with ultrastructural features very similar to normal corticopontine 
synaptic contacts. Therefore, it can be assumed that cortical neurons projecting to the pons 
maintain their ability to build new synapses during adulthood if provided with a permissive 
environment. The proof that bouton-like structures of sprouted fibers, as observed by light-
microscopy, most certainly correspond to intact synapses, provides morphological support 
that functional recovery of forelimb movements following pyramidotomy is at least partially 
due to neuronal plasticity and the establishment of new neuronal circuits (Thallmair et al., 
1998; Z'Graggen et al., 1998). These may compensate for some of the functions of the injured 
corticospinal tract. The exact physiological role of the discussed bilateral innervation 
following injury and treatment with IN-1 remains to be elucidated. Presumably, the new 
projections serve to balance and integrate motor and sensory signals in the cerebellum as a 
part of the cortico-ponto-cerebellar-thalamo-cortical feedback loop.  
 
As discussed in the introduction, not only the presence of a permissive environment but also 
the expression of certain molecules is necessary for axon outgrowth (Plunet et al., 2002). 
Axonal growth responses can be induced by treatment with IN-1 but also by certain types of 
axonal injury (Neumann and Woolf, 1999; Buffo et al., 2000; Bareyre et al., 2002). Neurons 
in the central nervous system are in general embedded in an intricate structural network that 
makes it difficult to investigate cell body responses to axotomy of a specific population of 
neurons. Because of the relatively low complexity of the dorsal root ganglia (DRG), we 
investigate the cell body response to axotomy in DRG neurons. Additionally, this system 
enables us to examine differences in the cell body response following injury to centrally 
versus peripherally projecting neuronal processes. Using microarrays, we find that the 
expression of more than 100 genes is either up- or down-regulated during developmental 
stages when axonal growth occurs in comparison to the adult animal. Sciatic nerve transaction 
as well as dorsal rhizotomy is able to induce profound changes in gene expression in the adult 
DRG. In both cases the expression of more than 50 genes is regulated, although for many 
genes, only one of the injury-types is a strong enough stimulus to change the expression. 
Surprisingly, we find for only about one third of the regulated genes following peripheral 
axotomy a recapitulation of the developmental expression pattern. The hypothesis that a 
developmental gene expression profile is needed for successful regenerative axonal growth 
does not seem to be adequate. Although, among the genes that recapitulate a developmental 
profile, some may be crucial for the ability to regenerate. Further, we describe a common 
theme of injury-induced regulation. If a peripheral and a central axotomy are evoking the 
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regulation of a given gene, the direction of the regulation is for both injury paradigms the 
same. This finding gives a hint that the direct injury-related cell body response may obey 
more general rules than widely believed. It may, therefore, reflect different environmental 
influences between the peripheral and central nervous system on the neuronal cell body 
response. Intrinsic differences between the central and peripheral axon of DRG neurons in 
propagating the signal that an injury has occurred to the cell body, may also play an important 
role. The gene expression profile can give first ideas about the functional properties of a 
neuron in terms of physiological processing or induced adaptive changes.  
 
The differential expression of glypican-1, a major heparan sulphate proteoglycan, turns out to 
be special in two way (for review see (Bandtlow and Zimmermann, 2000)). First, the mRNA 
expression of glypican-1 is high during development and induced by injury to the central as 
well as the peripheral branch of DRG neurons, a feature that is only shared by a few genes 
expressed in the DRG. In addition, we show that the initial cell body response following 
peripheral injury can still be intensified by a subsequent central injury. Therefore, it seems 
controversial whether there is a maximal cell body response following injury as it was 
postulated for peripheral axotomy.  Second, in uninjured adult DRG neurons, glypican-1 
protein is mainly localized to the nucleus. Following peripheral nerve injury, glypican-1 is 
distributed to the cell membrane, a change that is also seen following central injury. From 
these experiments we conclude that axotomy can affect, in addition to transcriptional changes, 
the subcellular protein localization of regulated genes. With the re-innervation of peripheral 
targets, glypican-1 expression is normalized. We present for the first time a detailed 
histological description of the mRNA expression of the slit family of repulsive guidance 
molecules and their receptor family, the robos, in the adult DRG and we provide evidence that 
glypican-1 may act as a co-receptor for the slit family or repulsive guidance molecules in 
uninjured as well as injured DRG neurons, since glypican-1 is co-expressed with robo-2.  
 
Here we report the appearance of peripheral benzodiazepine receptor (PBR) mRNA following 
sciatic nerve transsection with a concomitant increase in PBR protein from essentially 
undetectable levels in non-injured DRG neurons to presence in a defined subgroup of small-
caliber neurons. These finding underline another aspect of injury-induced regulation. 
Although axons of small-, medium- and large-diameter neurons are injured, the cell body 
response varies between subsets of neurons. It seems likely that the differential responses of 
neuronal subgroups depend on intrinsic properties of a given neuron, rather than on 
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environmental factors. The presence of PBR protein in a conformation that is able to bind a 
pharmacological ligand is demonstrated in the DRG and the dorsal horn of the spinal cord 
following injury. These results suggest that axotomy can change the responsiveness of a given 
neuron to environmental factors as shown here by the induction of a previously absent 
receptive molecule.  
 
In summary, this work shows that we can elicit adaptive axonal growth and the formation of 
new synapses in the injured adult central nervous system by counteracting Nogo-A, a major 
inhibitor of axonal growth. Axotomy evokes a cell body response that is to some degree 
dependent on environmental factors and on intrinsic properties of a given neuron itself. 
Injury-induced changes involve the widespread regulation of transcription, steps of post-
translational modification as well as protein localization in the cell body and protein transport 
along the axon.  
 
Many questions regarding the control of axonal growth remain to be asked and answered. IN-
1 induced plasticity of the cortico- and rubrospinal system has been studied extensively and 
has been correlated to functional recovery of the forelimb (for review see (Schwab, 2002). 
Less is known about plastic changes in the spinal cord induced or enhanced by IN-1 (Bareyre 
et al., 2002). Histological and behavioral analysis of ascending sensory fiber tracts after 
treatment with anti-Nogo-A antibodies is one crucial topic that we are currently working on. 
New antibodies recognizing specific sequences of Nogo-A are currently tested together with a 
method of spinal intrathecal drug delivery by miniosmotic pumps. We ask whether anti-Nogo-
A treatment following spinal cord injury alters segmental termination patterns of primary 
sensory afferents, a process that may affect proprioceptive and nociceptive processing in the 
spinal cord and may account for severe maladaptive changes, such as neuropathic pain and 
spasticity (for reviews see (Pearson, 2000; Edgerton et al., 2004; Woolf, 2004). This aspect is 
especially important regarding possible clinical application of anti-Nogo-A antibodies. 
Special tracing techniques including transganglionically transported molecules and a pseudo-
rabies virus based transsynaptic tracing method may be used to describe adaptive changes in 
local spinal networks. The molecular mechanisms that control regenerative axonal growth are 
under intense investigation. Recently, a neuronal receptor for Nogo-A and some proteins 
involved in the downstream signaling cascade have been found. It is not clear yet, to which 
extent the same molecules are involved in structural plasticity. Gene regulation following 
treatment with IN-1 in the intact or pyramidotomized animal revealed some genes with 
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potential functions in axonal growth and guidance, e.g. BDNF, semaphorins, slits, STATs 
(Bareyre et al., 2002). Further analysis using a proteomics approach may provide additional 
relevant information. Based on the results of our gene chip experiments, selected genes can be 
studied to determine their functional role in regenerative axonal growth. One approach is to 
use a genetically modified viral vector with a tropism for primary sensory neurons to over-
express the gene of interest in situations of neural injury (Seijffers and Woolf, 2004). In order 
to extend our knowledge about neuronal responses to injury, newly developed techniques 
such as single cell micro-dissection may be used to investigate the cell body response of 
subpopulations of neurons that truly lie within the central nervous system, e.g. pyramidal cells 
in the motor cortex.  
 
Recently mAb IN-1 was tested in a rat stroke model. Its application after an ischemic lesion in 
adult rats induced strong improvements in a food pellet reaching task that tests find hand 
movements, and established new cortico-fugal projections from the uninjured, opposite 
hemisphere . Unpublished results even demonstrated a positive effect on functional recovery 
after stroke if the antibody was applied with a delay of seven days following the injury (G.L. 
Kartje and M.E. Schwab). Preliminary results obtained from experiments with a humanized 
anti-Nogo-A antibody following unilateral cervical spinal cord injury in adult monkeys, 
revealed improved recovery of hand function (T. Wannier, E.M. Rouiller and M.E. Schwab). 
The present data about the action of anti-Nogo-A antibodies are very encouraging in terms of 
a potential clinical application in humans, primarily following spinal cord injury, with the 
possibility of subsequent application in stroke. Currently, preparations are under way in 
collaboration with Novartis and a group of clinical spinal cord injury centers for first 
toxicological studies in animal models and subsequently in humans. 
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